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Gastric cancer is the fourth most common cancer in the world and the 
second most common cause of cancer-related death. The rate of metastasis is high 
in gastric cancer patients. During cancer metastasis progression, the tumor cells 
underwent a plethora of molecular and morphological changes to become motile 
and invasive for the malignant transformation. Thus discovery of the molecules 
that were involved in metastasis progression is critical for early diagnosis and 
prognosis for gastric cancer patients. In this study, we aim to identify biomarkers 
for gastric cancer metastasis using a quantitative proteomics approach. The 
proteins extracted from a panel of 4 gastric cancer cell lines, two derived from 
primary cancer (AGS, FU97) and two from lymph node metastasis (AZ521, 
MKN7) were labeled with iTRAQ (8-plex) reagents and analyzed by 2D - LC 
MALDI-TOF/TOF MS. In total, 641 proteins were identified with at least a 95% 
confidence. Using cutoff values of >1.5 and <0.67, 19 proteins were found to be 
up-regulated and 33 were down-regulated in the metastatic versus primary gastric 
cancer cell lines respectively. 
Among these dysregulated proteins, fascin and UCHL1 expressions were 
increased while caldesmon expression decreased in the metastasis-derived cancer 
cell lines as verified by western blotting. The trend of expression of fascin and 
caldesmon in the metastasis-derived cell lines were further confirmed by the 
analysis of a panel of eleven gastric cancer cell lines. Furthermore, 
immunohistochemical staining of 9 pairs of primary gastric cancer tissues and the 
matched lymph node metastasis tissue also corroborated this observation. Tissue 
microarray analysis showed that fascin expression was correlated with gastric 
cancer serosal invasion and lymph node metastasis. In patients with well-
differentiated gastric cancer, positive expression of fascin is associated with 
poorer survival. On the other hand, the expression of caldesmon in tumor tissues 
was scarce. Pericellular caldesmon expression is correlated with serosal invasion.  
xii 
 
As caldesmon is a novel target associated with gastric cancer, we studied 
its function in gastric cancer cell lines. Knockdown of caldesmon using siRNA in 
AGS and FU97 gastric cancer cells resulted in an increase in cell migration and 
invasion, while the over-expression of caldesmon in AZ521 cells led to a decrease 
in cell migration and invasion, and increase in cell adhesion. To elucidate 
caldesmon interacting partners, co-immunoprecipitation coupled to in-gel 
digestion experiment identified myosin, tropomyosin and other actin cytoskeleton 
regulating proteins as caldesmon interacting proteins. This study has thus 
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CHAPTER 1 INTRODUCTION 
 
1.1 GASTRIC CANCER 
1.1.1 Gastric Cancer Epidemiology 
 
Gastric cancer is a malignancy that usually arises from the inner 
epithelial linings of the stomach. In 2008, with approximately 990,000 new 
cases and 738,000 cancer related death around the globe, GC ranked as the 
fourth most common malignancy and the second leading cause of cancer 
related death in the world (Jemal et al., 2010). The incidence rates of gastric 
cancer are high in Asia, Eastern Europe and parts of Central and South 
America. The disease incidence rates are about twice as high in males 
compared to females (Garcia et al., 2007). In Singapore, from 2006-2010, 
gastric cancer is the 5
th
 most common cancer in male (account for 6% of 
25,087 total cancer cases) and the 7
th
 most common cancer in female (4% of 
26,570 total cancer cases) (Singapore Cancer Registry). 
Despite a decreasing incidence rate of gastric cancer around the world 
in the recent 30 years (Garcia et al., 2007), the survival rate of gastric cancer 
remains poor. About 74% of people who were diagnosed with gastric cancer 
died of this disease in 2000 (Hartgrink et al., 2009). The 5-year survival rates 
for gastric cancer patients are only around 24% in US and Europe (Brenner et 
al., 2009; Garcia et al., 2007). In Singapore, the post-resection 2-year survival 
rates are only 40% (Look et al., 2001). The poor prognosis rate of gastric 
cancer poses a health burden and there is a pressing need to develop novel 




1.1.2 Gastric Cancer Risk Factors 
 
The best established risk factor for gastric cancer, especially the distal 
gastric cancer is Helicobacter pylori infection (Brenner et al., 2009). In 1994, 
the International Center for Cancer Research officially recognized 
Helicobacter pylori as a carcinogen for gastric cancer (Ito et al., 2009). 
Helicobacter pylori is a Gram-negative bacterium which localized mainly 
extracellularly within the gastric lumen. It is estimated to be present in over 50% 
of the human population and it is highly adaptable in colonizing the stomach 
epithelium (Piazuelo et al., 2010), leading to gastritis and chronic infection 
which may eventually develop into gastric cancer. The attributable risk for 
gastric cancer conferred by Helicobacter pylori is approximately 75% (Polk & 
Peek, 2010). A large scale clinical trial involving 2-weeks antibiotic treatment 
to eradicate Helicobacter pylori followed by 7 years of dietary vitamin 
supplement reduced gastric cancer risk over a follow-up period of 15 years 
(Ma et al., 2012).  
Other risk factors associated with gastric cancer include smoking 
(Catalano et al., 2009), and high salt intake (in excess of the WHO 
recommended maximum of 5 gram of salt intake per day) (Peleteiro et al., 
2011). For example, a meta-analysis of over a hundred epidemiology studies 
found that approximately 50% of the increased risk of gastric cancer was 
associated with the intake of high-salt pickled vegetables, especially in China 
and Korea (Ren et al., 2012). Consumption of several types of meat, high-fat 
dairy foods, starchy food and sweets (“unhealthy” diet) also increased the risk 
of gastric cancer by 50%, whereas consumption of large quantity of fruits and 
non-starchy vegetables, including allium vegetables (garlic, onions etc.) 
(prudent/healthy diet) may decrease the risk of gastric cancer by 25% 
(Bertuccio et al., 2013; Catalano et al., 2009). 
3 
 
Age, gender, and ethnicity may also be related to gastric cancer risk. In 
Singapore, the Chinese males have higher risk of gastric cancer compared to 
the Malay and Indian counterparts. The incidence rates of gastric cancer also 




1.1.3 Gastric Cancer Histological classifications 
 
Two types of gastric cancer have been defined by Lauren’s classification 
based on the tumor histology (Lauren, 1965): the intestinal type and the diffuse 
type. The intestinal type has retained well-defined glandular structures surrounded 
by stroma and resembled the adenocarcinoma arising in the intestinal tract 
(Catalano et al., 2009). It is often associated with a multi- step neoplastic 
development which started with Helicobacter pylori infection induced chronic 
gastritis, intestinal metaplasia, dysplasia and eventually adenocarcinoma 
(Hartgrink et al., 2009; Polk & Peek, 2010). The diffuse type consists of 
individual infiltrating neoplastic cells that do not form glandular structures (Polk 
& Peek, 2010) and have low cell-cell adhesions (Catalano et al., 2009).  
Gastric cancer can be defined as well/moderately- , or poorly-differentiated 
subtypes based on the degree of glandular differentiation (Broders, 1925). The 
well/moderately-differentiated gastric cancers are often classified into intestinal 
type, whereas the poorly-differentiated subtype usually corresponds to diffuse 
type in Lauren’s classification (Tahara, 2004). 
Gastric cancer may also be classified into two types based on different 
growth and invasion patterns: the expanding type which contains discrete tumor 
nodules, may arise from intestinal metaplasia, and have better prognosis; and the 
infiltrating type which contains individual invading cells, of which the prognosis 




1.1.4 Screening and Diagnostic Tools for Gastric Cancer 
 
The stomach epithelial lining undergo precancerous changes which were 
often long and asymptomatic (averaging 44 months) (Tsukuma et al., 2000) 
before gastric cancer development. For early gastric cancer cells, it was observed 
that their doubling time is approximately 16.6 months (Haruma, 1991). Hence, 
screening and early diagnosis of gastric cancer is necessary for disease 
intervention. Helicobacter pylori screening and treatment for positive cases, 
endoscopic screening of pre-malignant gastric lesions are commonly used 
diagnostic tools for the early detection and prevention of gastric cancer (Areia et 
al., 2013) In Japan, the high risk population was screened annually with barium 
meal or endoscopy for possible gastric cancer (Leung et al., 2008). However, 
these detection methods were limited by the size of the tumor (barium study) and 
the skills of the endoscopists.  
A measurement of serum pepsinogen level combined with Helicobacter 
pylori antibody status may be a useful non-invasive serological screening method 
(Leung et al., 2008). Pepsinogen (PG) is an inactive precursor of pepsin: a 
gastrointestinal enzyme produced in the gastric mucosae. Approximately 1% PG 
entered the blood circulation and a reduction of serum PGI as well as PG I/II ratio 
was correlated with gastric mucosal atrophy progression. The patients who tested 
positive in the pepsinogen test with progression of chronic atrophy gastritis have 
higher risk of developing into gastric cancer, thus might be classified into high- 
risk group and are monitored closely (Enomoto et al., 2010). However, the serum 
pepsinogen test is limited in the detection of intestinal-type gastric cancer which 





1.1.5 Treatment Options for Gastric Cancer 
 
The therapeutic options for gastric cancer are endoscopic mucosal resection 
(EMR), endoscopic submucosal dissection (ESD), surgical gastrectomy and 
chemotherapy (Katoh, 2005). Randomized clinical trials have shown that a 
combination of pre-operative radiotherapy combined with surgery improved the 
patients’ survival (Hartgrink et al., 2009). The overall survival in patients with 
resectable gastric cancer has been significantly improved with use of either post-
operative chemo-radiation or peri-operative ECF (Epirubicin, Cisplatin and 
Fluorouracil) (Knight et al., 2013). For the inoperable advanced stage gastric 
cancer which consisted of 80-90% of total cases, chemotherapy based on drug 
combinations, like 5-FU/platinum drug combinations, as well as irinotecan and 
docetaxel-combination are current treatment options (Wagner et al., 2010). 5-FU 
is a pyrimidine analogue which blocks thymidine synthesis and subsequent DNA 
replication by inhibiting thymidilate synthethase. The platinum-containing drugs 
Cisplatin and oxaliplatin crosslink DNA, which leads to the apoptosis of cancer 
cells. Irinotecan exerts the anti-cancer effect by acting as a DNA topoisomerase 
inhibitor, whereas docetaxel inhibits cancer cell division by preventing the 
depolymerization of microtubules (Wagner et al., 2010). The administrations of 
these cytotoxic drugs have adverse effects on normal cells as well and patients 
often suffer from severe side effects with poor prognosis: the 5-year survival rates 
are only approximately 20% (Catalano et al., 2009). 
Besides the conventional anti-cancer therapies, research on targeted therapy 
which involves monoclonal antibodies or small molecules specifically inhibiting 
certain oncogenes has been underway. It is believed that the targeted therapy will 
be focused on eliminating only the cancer cells with minimal side effects on the 
normal cells. The identification of the oncogenic pathways and gastric cancer 
biomarkers are critical in this context. Investigation of targeted therapy to gastric 
cancer is under clinical Phase II trials with monoclonal antibodies targeting 
oncogenes such as ERBB2, VEGF (Hartgrink et al., 2009). Recently Trastuzumab, 
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a monoclonal antibody against Human epidermal growth factor receptor 2 
(HER2), has been approved by the FDA to use in combination with chemotherapy 
for treating the metastatic gastric adenocarcinoma with HER2- over-expression 




1.1.6 Molecular Patterns and Biomarkers for Gastric Cancer 
 
Gastric cancer is a heterogeneous disease. It has been estimated that 80-90% 
gastric cancers were developed sporadically, 10-20% occurred in family clusters, 
and 1-3% have genetic susceptibility (Saghier et al., 2013). Identification of these 
molecules that were involved in the carcinogenesis is critical for the early 
detection of disease, and stratification for the appropriate treatment and disease 
prognosis. The most widely used cancer-associated antigen, carcinoembryonic 
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are found to be elevated 
in only 30-40% of primary gastric cancer patients (Catalano et al., 2009).  
A recent study has found human epithelial growth factor receptor 2 (HER2), 
a member of the human epidermal growth factor receptor family, is over-
expressed in approximately 9-38% of gastric cancer (Gravalos & Jimeno, 2008), 
especially in the intestinal type of gastric cancer. Over-expression of HER2 in 
intestinal type gastric cancer is also correlated with poorer survival (Chua & 
Merrett, 2012). A large scale Phase III clinical trial (ToGA) using Trastuzumab 
(Herceptin) combined with chemotherapy in HER2 positive gastric cancer 
patients has effectively improved the patients’ 5-year survival by 3 months (Hu et 
al., 2012; Saghier et al., 2013). It is recommended to conduct HER2 screening at 
the initial gastric tumor diagnosis for targeted therapy (Rüschoff et al., 2012). 
Cell cycle regulators have also been found to be dysregulated in gastric 
cancer. Cyclin E over-expression has been identified in 15-20% of gastric cancer 
patients. A reduction of p27
Kip1
, a cyclin-dependent kinase (CDK) inhibitor is 
associated with advanced stage gastric cancer (Yasui et al., 2005). 
Cell adhesion molecules are associated with gastric cancer progression. It 
has been observed that increased expression of β-catenin which was involved in 
cell-cell adhesion and gene transcription activation expressed in up to 50% of 
gastric cancer. The increased β-catenin could be attributed to the translocation of 
Helicobacter pylori cytotoxin-associated gene A (CagA) protein which induced 
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nuclear accumulation of β-catenin and subsequent gene transcription upon the 
bacteria infection (Polk & Peek, 2010). 
Patients with germ-line mutation of CDH1 (gene encodes for E-cadherin 
expressed at the adherence junction) had a high chance of developing into familial 
diffuse type gastric cancer (Katoh, 2005). The expression level of CD44, a 
membrane-bound glycoprotein involved in cell adhesion may be associated with 
gastric cancer lymph node metastasis (Hsieh et al., 1999).An 
immunohistochemical study has established a combination of CD44 and 
epithelial-mesenchymal transition related proteins Snail-1, vimentin and E-
cadherin have prognostic significance in predicting the gastric cancer patients’ 
survival (Ryu et al., 2012). 
The 4 gastric cancer cell lines AGS, AZ521, FU97 and MKN7 used in this 
study have been adopted in various gastric cancer biomarker researches. The AGS 
cell line, derived from a specimen of human stomach adenocarcinoma, possess 
some characteristics of normal gastric epithelial cell such as epithelial-like 
morphology (Zheng et al., 1996). AGS cells expressed PLA2G2A phospholipase 
which has an anti-invasion effect, while MKN7 and FU97 did not express this 
protein (Ganesan et al., 2008). The expressions of metastasis-related proteins 
have been studied in gastric cell lines. A loss of expression of E-cadherin, a 
marker for epithelial cell adherence junction, has been observed in AZ521 
(Yonemura et al., 2000). Vascular endothelial growth factor-C (VEGF-C), a risk 
factor associated with gastric cancer metastasis, has been found to be expressed in 
AZ521 but not in MKN7 (Yonemura et al., 1999). Using a panel of gastric cancer 
cell lines including AGS, MKN7, AZ521, EZH2, a critical component of 
polycomb repressive complex 2 (PRC2) was identified to have increased 
expression levels associated with gastric cancer progression (Cheng et al., 2012). 
A large scale genomics profiling of 37 gastric cancer cell lines have identified two 
major genomic subtypes coined as G-INT and G-DIF which is partially associated 
with Lauren’s histopathologic classification. AGS was in the G-INT group, while 
FU97, MKN7 and AZ521 were classified into G-DIF group (Tan et al., 2011).  
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1.2 CANCER METASTASIS 
1.2.1 TNM Staging of Tumor, Lymph Node Metastasis 
 
Cancer staging provides histological summary of the tumors and is useful 
for decision on treatment as well as prognosis of disease. The TNM classification 
for gastric cancer has been widely adopted (Sobin and Wittekind, 2002). The 
TNM staging criteria for gastric cancer are listed in Table 1.1 below (adapted 
from Catalano et al., 2009). T is used to describe the size and invasion depth of 
tumor. Tx or T0 is defined as no evidence of primary tumor. Tis is defined as 
carcinoma in situ. T1 tumor has invaded lamina propria/submucosa. T2 tumor 
penetrated muscularis propria or submucosal. T3 tumor invaded stomach serosa, 
while T4 tumor has invaded stomach adjacent structures including spleen, colon, 
liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, 
retroperitoneum etc. N defined the tumor involvement of regional lymph nodes. 
Nx or N0 meant no lymph node metastasis. N1 tumor has metastasized to 1-6 
regional lymph nodes, N2 to 7-15 regional lymph nodes, and N3 to more than 15 
regional lymph nodes. M defined the status of distant metastasis. Mx or M0 has no 





TNM Stage Description 
T Size, invasion depth of tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina 
propria 
T1 Tumor invaded lamina propria or submucosa 
T2 Tumor invaded muscularis propria or submucosa 
T2a Tumor invaded muscularis propria 
T2b Tumor invaded submucosa 
T3 Tumor invaded serosa without invasion of adjacent structures 
T4 Tumor invaded adjacent structures (Spleen, transverse colon, liver, 




Involvement of regional lymph nodes (a minimum of 15 lymph nodes 
examined) 
NX Regional lymph node cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-6 regional lymph nodes 
N2 Metastasis in 7-15 regional lymph nodes 
N3 Metastasis in more than 15 regional lymph nodes 
M Distant metastasis 
MX Presence of distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis. 
 




1.2.2 Metastasis Is a Multi-Step Process 
 
Metastasis, the spread of tumor from the primary organ to a distant part of 
the body (Talmadge & Fidler, 2010), is responsible for as much as 90% of cancer-
related death (Chaffer & Weinberg, 2011). The ability of tumor cells to activate 
invasion and metastasis is coined as one of the hallmarks of cancer (Hanahan & 
Weinberg, 2011).  
The growth of primary tumor was slow. To reach a 1cm diameter 
(minimum size for detection with current imaging tools) which has approximately 
10
9
 cells, at least 30 doublings (average 12 years) of the tumor cells were required. 
However the tumor only required 10 doublings to grow from 1 cm diameter to the 
size of 1000 cm
3
 which was lethal (Talmadge & Fidler, 2010). Therefore a better 
understanding of the metastasis mechanism and its molecular phenotype is 
required for early detection of cancer and prediction of disease outcome. 
In order for metastasis to occur, tumor cells undergo a series of 
progressions consisting of detachment of tumor cells, local invasion and 
angiogenesis, gaining motility to enter the circulation, vessel invasion, adhesion 
to endothelial cells and extravasation, and growth in distant organs (Yasui et al., 
2005). 
It is hypothesized that metastasis may have occurred prior to tumor 
diagnosis. Studies have found that metastases exhibit substantial differences in the 
gene expression profiles when compared to that of the primary tumors (Sleeman 
& Steeg, 2010). It has thus been proposed that the ectopically residing tumor cells 
may have disseminated in the early stage and developed independently into 
metastases in parallel with the primary tumor development (Stoecklein & Klein, 
2010). Genome-wide analysis of 4 breast cancer samples: primary tumor, 
peripheral blood, brain metastasis and xenograft developed from primary tumor 
isolated from the same patient discovered that tumor metastases has retained the 
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mutations existed in primary tumor with higher frequency, and carried de novo 
mutation not found in the primary tumor (Ding et al., 2010). This finding 





1.2.3 Molecular Features of Metastasis 
 
The expressions of many proteins and metabolites are perturbed during 
metastasis progression. These dysregulations probably resulted from the increased 
energy demand, gaining of motility and invasiveness of the metastasizing cancer 
cells. These molecular features might serve as potential biomarkers for metastasis. 
Activation of oncogenic signaling pathways is an important feature for 
cancer progression and metastasis. Amplification of tyrosine kinase MET has 
been observed in certain gastric cancer (Gherardi et al., 2012). Activation of 
Notch signaling promoted gastric tumor growth and metastasis via activation of 
STAT3 and Twist mediated signaling cascade (Hsu et al., 2012). 
Increased expression of metabolic proteins involved in glycolysis, the citric 
acid cycle, oxidative phosphorylation, β-oxidation, the glutathione system, and 
the pentose pathway were observed in breast cancer metastasis, implying that the 
metastatic cancer cells gain energy mainly through glycolysis (Chou & Chan, 
2012). Studies have found that differentially-expressed metabolites between 
metastatic and non-metastatic gastric cancer include those involved in glycolysis 
(lactic acid, alaine), nucleotide metabolism (pyrimidine), and fatty acid 
metabolism etc. The increased production of lactic acid in metastatic cancer may 
reflect the increased energy demand for tumor progression (Chen et al., 2010).  
Decreased cell-cell adhesion, re-arrangement of the actin cytoskeleton, and 
increased motility and cell invasiveness are distinct characteristics of metastatic 
cancer cells compared to the normal epithelial cells (Katoh, 2005; Voulgari & 
Pintzas, 2009). Actin cytoskeleton mediates cell morphology, cell migration and 
cell-cell attachment. During metastasis, gaining of motility in cancer cells has 
been observed for the cancer cells to breach through the basement membrane with 
actin filament-enriched cellular processes (Bravo-Cordero et al., 2012). 
Invadopodia, an actin-enriched cellular protrusion that degraded the extracellular 
matrix, facilitate the invasion of metastatic cancer cells (Bravo-Cordero et al., 
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2012). The expression perturbations of proteins which regulate actin 
polymerization, actin bundling and invadopodia formation are present in 
metastasis. Reduction of E-cadherin, an increase of RhoA/ROCK-mediated actin 
cytoskeleton re-organization signaling networks have been observed in cancer cell 
migration (Spano et al., 2012). Actin bundling protein fascin is often seen as up-
regulated in metastatic cancer, and up-regulation of non-muscle myosin’s activity 
which mediated cell contractility and stiffness has been observed in advanced 
stage cancer (Stevenson et al., 2012).  
Proteins which are involved in tissue remodeling in inflammation, like 
osteopontin (OPN), an inflammatory cytokine, and SPARC, a stress-response 
protein (Chiodoni et al., 2010), proteolytic enzymes like matrix 
metalloproteinases (MMPs) which may play a role in degrading the basement 
membrane (Brooks et al., 2010) were found to be expressed in metastatic cancer 
cells. The expressions of specific adhesion molecules involved in crosstalks 
between migrating cancer cells and their microenvironment were also observed 
(Chaffer & Weinberg, 2011). The over-expression of chemokine ligands (CCLs) 
CCL7 and CCL21 in gastric cancer was correlated with lymph node metastasis 
and poor survival. It was postulated that over-expression of CCLs may recruit 
myeloid cells which expressed chemokine ligand receptor and produced MMPs to 




1.3 PROTEOMICS: A HIGH-THROUGHPUT METHOD IN 
UNDERSTANDING THE MECHANISMS OF CANCER 
1.3.1 Proteomics in Cancer Marker Discovery 
 
Protein biomarkers for cancer diagnosis and prognosis are valuable tools 
that complement traditional cancer staging methods. They may improve the 
effectiveness of clinical intervention, stratify the patients to the most appropriate 
treatment, and predict cancer recurrence after treatment (Tainsky, 2009). 
Currently the cancer biomarkers used in clinics include serum-based markers 
Alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate 
dehydrogenase (LDH) for patients with metastatic nonseminomatous germ cell 
tumors (NSGCTs); human epidermal growth factor receptor 2 (HER-2), urokinase 
plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) for 
breast cancer prognosis (Duffy & Crown, 2008). However, these biomarkers may 
have limited diagnostic power with sensitivity and specificity that are not optimal.  
Proteomics refers to the study of entire protein complement expressed by 
the genome. It involves the large-scale identification, quantitation and 
characterization of proteins expressed in cells or tissues in a given condition (He 
& Chiu, 2003). In cancer cells, both the transcriptional programs and the post-
translational protein modifications are altered for cancer cells to gain the growth 
and motility advantage. The challenge to capture these global changes in protein 
expression has been met by high-throughput proteomics approach (Chen & Yates, 
2007). Studies have found that while the current gastric cancer marker 
carcinoembryonic antigen (CEA) has only 49% sensitivity, a panel of peptide 
mass fingerprinting identified with surface-enhanced laser desorption/ionization 
(SELDI) proteomics with gastric cancer serum samples yielded 83% sensitivity 
and 95% specificity (Cho, 2007; Poon et al., 2006). However, many still remain 
to be understood for cancer progression, and biomarkers which can better predict 
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cancer occurrence, diagnose early cancer and predict patients’ survival are 
urgently in need. 
The samples for cancer proteomics studies vary from cancer cell lines, 
tumor tissues or body fluids/plasma. Cancer cell lines have high degree of 
homogeneity and are easy to handle. They can be genetically manipulated for 
functional studies. However they are prone to genotypic and phenotypic drifts 
over prolonged culturing time, and thus may not resemble 100% of the original 
tumor from which they were isolated. Tumor tissues and body fluids/plasma are 
good models for subsequent clinical applications, however the tumor samples are 
often limited and inherent variance exist among different patients. The complexity 
in plasma sample and the dynamic range in protein concentrations may also pose 




1.3.2 Proteomics Techniques: Gel-based platforms 
 
The two-dimensional gel electrophoresis (2D-GE), a gel-based technique, 
is a classic proteomics approach. The proteins are fractioned on the first 
dimension based on their isoelectric points (pI) using isoelectric focusing (IEF), 
followed by separation by molecular weight via sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Görg et al., 2000). Difference –
in- gel electrophoresis (DIGE) method allows for quantification with 
incorporation of CyDye fluors (Cy2, Cy3, and Cy5) by covalently labeling the ε- 
amino group of lysines in two different samples. Equal amount of the two samples 
are combined and run in a single first dimensional IEF gel. The same protein 
labeled with any of the fluors will be resolved as the same spot and the relative 
expression across samples is reflected when comparing intensity of the spots (Wu 
et al., 2006). Several inherent problems are associated with 2D-GE and DIGE 
approach: Proteins of low abundance, extreme pI and molecular weight cannot be 
identified due to the detection limit of 2D-GE. Proteins of similar pI and size may 
co-migrate to the same spot, and the gel-to-gel variation between batches may 




1.3.3 Proteomics Techniques: LC-based platforms 
 
LC-based proteomics methods choose a variety of stationary and mobile 
phases to resolve complex biological samples. Generally, the proteins are first 
digested into peptides, followed by separation with strong cation exchange and 
then with reverse phase chromatography (Wu et al., 2006). Quantitative methods 
involved in LC-based approach include Stable-isotope labeling by amino acids in 
cell culture (SILAC), cleavable Isotope-coded affinity tag (cICAT) labeling, and 
isobaric tags for relative and absolute quantitation (iTRAQ). 
In the SILAC approach, cells are grown in media with normal amino acids 
(
12
C) or in the media with non-radioactive, isotope-coded form of specified amino 
acids (
13
C). The isotopic labeling can be achieved in 4-5 cell doubling times and 
the temporal dynamics of proteins can be quantified based on the light-to-heavy 
isotope ratio (Chen & Yates, 2007). The SILAC method can only be applied in 
cell line models but not tissue samples.  
In the cICAT approach, proteins from two states on cysteinyl residues are 




C) carrying a biotin moiety. The 
labeled proteins are then mixed, digested and affinity purified using avidin 
(Chaerkady & Pandey, 2007). Peaks corresponding to the same peptide are 
identified as doublets in the mass spectra due to the mass difference between light 
and heavy isotopes. The peak intensities of the peptides correlate with the relative 
abundance of the proteins in the two states. Due to the affinity purification step 
involved, cICAT technique can only identify proteins containing cysteinyl 
residues (Wu et al., 2006). 
In iTRAQ approach, 4-plex or 8-plex isobaric tags consisting of reporter 
mass of 114-117 (4-plex) or 113-121 (excluding 120, 8-plex), a corresponding 
balance group and an amine-reactive group are used to label primary amino group 
in peptides. The labeled samples are pooled, fractionated and subjected to mass 
spectrometry whereby MS/MS fragmentation release the reporter ions which 
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would reflect the relative abundance of the proteins (Chaerkady & Pandey, 2007). 
The iTRAQ approach allows for multiplexing of up to 8 samples. In a recent 
study, the proteome of 2 distinct panels of isogenic prostate cancer cells with 
varying growth and metastatic potential were profiled with 8-plex iTRAQ 
analysis. Of the 245 proteins identified and quantified, 17 proteins were 
significantly differential expressed and potentially associated with metastasis 
progression (Glen et al., 2010). 
These three quantitative proteomics approaches: DIGE, cICAT and iTRAQ 
have been compared recently in regard to their sensitivity (number of peptides 
detected for each protein) and proteins profiling using six-protein mixture and 
cancer cell lysates. It is found that while DIGE is as sensitive as cICAT approach, 
iTRAQ has a higher sensitivity than the cICAT and DIGE method, and may have 
a higher chance of identifying low abundance proteins. The three methods 
covered cell lysates protein profiles which have little overlaps, suggesting that 




1.3.4 Proteomics in Gastric Cancer Biomarker Discovery 
 
There have been several publications that used proteomics approach to 
identify potential gastric cancer biomarkers. Many of them focused on markers 
that differentiate the early cancer from the normal gastric tissues, whereas those 
directed towards unraveling the proteome differences between metastatic and 
primary gastric cancers were relatively scarce.  
In a 2D-GE approach, 152 human gastric cancer tissue samples were 
analyzed (Cho et al., 2009), and it was reported that Rho GDP dissociation 
inhibitor 2 (RhoGDI2) to be positively linked to tumor growth and invasion, 
which was confirmed by tissue immunohistochemistry, cell-based functional 
assays and tumor growth study in nude mice. In one study, up-regulation of heat 
shock proteins, glycolytic enzymes, cytokeratin 8 and tropomyosin isoform, and 
down-regulation of cytokeratin 20 were observed via analyzing 10 paired tumors 
versus normal tissue samples in a 2D-GE approach (He et al., 2004). In another 
DIGE study, 13 dysregulated proteins involved in protein synthesis, metabolism 
and cytoskeleton were found in a highly metastatic gastric cancer cell MKN-45-P 
compared to its parental cell line MKN-45 (Takikawa et al., 2006). The proteome 
difference between a well-differentiated, non-metastatic gastric cancer cell line 
SC-M1 and its metastatic counterpart TMC-1 were compared using isotope-coded 
affinity tagging (ICAT) analysis, and several dysregulated proteins including up-
regulation of vimentin and galectin-1 were identified and verified in the same cell 
line (Chen et al., 2006). In a recent study, iTRAQ analysis of a gastric cancer cell 
line MKN7 and a normal gastric epithelium cell line HFE145 identified SLC3A2 
cell membrane protein to be a potential gastric cancer biomarker (Yang et al., 
2012). However, few of these studies performed functional validations of the 







Cancer metastasis is a major cause of death in cancer patients. The 
molecular events underlying gastric cancer metastasis remains to be discovered. 
In this study, we aim to identify the potential biomarkers for gastric cancer 
metastasis and also to investigate the functional roles of these proteins. We 
analyzed the cellular proteome of 4 different gastric cancer (GC) cell lines with 
isobaric tags for relative and absolute quantitation (iTRAQ) technology and 
MALDI-TOF/TOF MS. These GC cell lines consisted of 2 primary (AGS, FU97) 
and2 lymph node metastatic (AZ521, MKN7) gastric cancer cells. In addition, 
among these 4 cell lines, we have also included the two major histological 
subtypes of gastric cancer: (a) well/moderately differentiated (AGS, MKN7) and 
(b) poorly differentiated (FU97, AZ521) for proteome analyses with the view to 
identify the dysregulated proteins involved in gastric cancer metastasis in both 
histological subtypes. With the benefit of iTRAQ multiplexing, a panel of 4 cell 
lines with their technical replicates was incorporated in this study. This is in 
contrast to the previous gastric cancer cell line-based proteomics studies that 
compared only 2 cell lines. In order to discover the dysregulated proteins in 
gastric cancer metastasis and to understand their functional roles in metastasis, we 
plan to carry out the following:  
1. In the proteomics discovery phase, iTRAQ technology is used to 
perform comparative proteomics of four gastric cancer cell lines: two 
from primary cancer and two from lymph node metastasis, with paired 
differentiation subtype. The expression of dysregulated proteins would 
be verified by Western blotting and tissue immunohistochemistry. 
2. Functional studies to correlate the protein expression differences with 
the metastatic phenotype. Identify potential target involved in gastric 
cancer metastasis from the findings from the proteomics study. Perform 
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functional studies based on gene knockdown and over-expression as 
well as cell-based assays to examine the function of potential 




Chapter 2 MATERIAL AND METHODS 
2.1 CELL CULTURE 
 
The gastric cancer cell lines used in this study include AGS, NCI-N87 
(American Type Culture Collection (ATCC), Manassas, VA); AZ521, FU97, 
MKN7, MKN74 (Japanese Collection of Research Bioresources (JCRB), Osaka, 
Japan); and SNU16 (ATCC), YCC1, YCC2, YCC3, YCC9 (Yonsei Cancer 
Center, Seoul, South Korea) which were a kind gift from Prof Sun-Young Rha 
(Yu et al., 2008). The isolation sources of these cell lines and descriptions of the 
stomach tumor pathology were listed in Table 2.1. The cells were cultured in 
RPMI-1640 media (Sigma, St. Louis, MO) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (Gibco, Grand Island, NY) and 1 mM sodium 
pyruvate (Invitrogen, Carlsbad, CA) in a humidified incubator (37 °C, 5% CO2). 
Upon reaching 90% confluency, the cells were harvested with 0.05% (v/v) trypsin 
– 0.53 mM EDTA solution (Gibco). The cells were pelleted by centrifuging at 
1,000 g for 5 min at 15 °C. The cell pellets were washed thrice in phosphate-





Cell line Source  Description of tumor pathology  
AGS  Stomach  Moderately-differentiated gastric 
adenocarcinoma 
FU 97  Stomach  Poorly differentiated adenocarcinoma  
MKN 7  Stomach lymph node  Well differentiated adenocarcinoma  
AZ 521  Stomach lymph node  Poorly differentiated adenocarcinoma 
MKN 74  Stomach cancer liver 
metastasis.  
Moderately differentiated adenocarcinoma  
NCI-N87  Stomach cancer liver 
metastasis 
Well differentiated adenocarcinoma  
SNU 16 Stomach cancer ascites Poorly differentiated adenocarcinoma 
YCC 1 Stomach cancer ascites Adenocarcinoma 
YCC 2 Stomach cancer ascites Adenocarcinoma 
YCC 3 Stomach cancer ascites Adenocarcinoma 
YCC 9 Stomach cancer ascites Adenocarcinoma 
 
Table 2.1 Cell lines used in this study.  The table displays information of 





2.2 QUANTITATIVE PROTEOMICS USING ITRAQ 
2.2.1 Cell Lysates Preparation 
 
The harvested cells were lysed in iTRAQ labeling buffer (Sadowski et al., 
2006) that comprised of 25 mM Triethylammonium bicarbonate (TEAB), 8 M 
urea, 2% Triton X-100, 0.1% SDS, 50 µg/ml DNase I, 50 µg/ml RNase A, and 
1×Halt protease inhibitor cocktail (Pierce, Rockford, IL), and centrifuged at 
18,800 × g for 1h at 15 °C.  
The supernatants were then collected, and their protein concentrations were 
determined using the Coomassie Plus Protein Assay reagent kit (Pierce, Rockford, 
IL), and bovine serum albumin (BSA) as the calibration standard. The absorbance 
of the dye-protein complex was measured at 595 nm in a microtitre plate. 
2.2.2 iTRAQ Labeling 
 
The samples were labeled with iTRAQ reagents according to the 
manufacturers’ instructions shown in Figure 2.1. Duplicates of 100 µg of proteins 
from each of the 4 cell lines (AGS, FU97, AZ521 and MKN7) were reduced with 
5 mM tris-(2-carboxyethyl phosphine (TCEP) at 20 °C for 1 h, followed by 
alkylation with 10 mM methyl methanethiosulfonate (MMTS) for 10 min at room 
temperature. The samples were diluted 10 fold with 50 mM TEAB to reduce the 
SDS and urea concentrations, and subjected to trypsin (10 µg each) digestion at 
37 °C for 16 h with constant shaking.  
iTRAQ reagents (8-plex) (AB SCIEX, Foster City, CA) were each 
reconstituted in 50 µl of isopropanol. Each tryptic digest was labeled with iTRAQ 
reagents for 2 h at room temperature based on the following: AGS labeled with 
113 and 117, AZ521 labeled with 114 and 118, FU97 labeled with 115 and 119, 
and MKN7 labeled with 116 and 121. After labeling, the samples were pooled 
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together and passed through a strong cation exchange (SCX) cartridge as 
recommended by the manufacturer (AB SCIEX), followed by desalting with a 
reverse phase Sep-Pak C18 cartridge (Millipore, Marlborough, MA). The sample 
was vacuum dried and reconstituted for 2D-LC. 
 
 
Figure 2.1 Experimental workflow. The cell pellets from 4 gastric cancer cell 
lines: AGS, MKN7, FU97 and AZ521 were lysed and protein was extracted. 100 
µg of proteins were digested by trypsin and were labeled with iTRAQ 8 plex 
reagents. The samples were pooled and separated on 2D-liquid chromatography 
and subject to MALDI-TOF/TOF MS analysis. The protein IDs were searched 
against International Protein Index (IPI) human database (v. 3.72) with Protein 
Pilot 
TM





2.3 TWO-DIMENSIONAL LIQUID CHROMATOGRAPHY 
 
The iTRAQ-labeled peptide mixture was separated by the Ultimate
TM
 3000 
LC system (Dionex-LC Packings, Bannockburn, IL) (Hou et al., 2013; Tan et al., 
2008). A 2-D LC separation was performed as follows: the labeled peptide 
mixture was dissolved in 2% acetonitrile (ACN) with 0.05% trifluoroacetic acid 
(TFA) and injected into a strong cation-exchange (SCX) column (Dionex-LC 
Packings) for the first dimensional separation. The mobile phase A and B were 5 
mM KH2PO4 buffer, pH 3, with 5% ACN and 5 mM KH2PO4 buffer, pH 3, with 5% 
ACN and 100 mM KCl, respectively. 10 fractions were obtained using step 
gradients of mobile phase B: unbound, 0-2, 2-4, 4-6, 6-10, 10-20, 20-30, 30-40 
and 40-100% B. The eluting fractions were captured alternatively onto two trap 
column (Dionex-LC Packings) and eluted with an organic solvent gradient in a 
reverse-phase column (Dionex-LC Packings). The mobile phase A and B used for 
the second-dimensional separation were 100% H2O with 0.05% TFA and 100% 
ACN with 0.04% TFA, respectively. The gradient elution step was 0-60% B in 15 
min. The LC fractions were mixed directly with MALDI matrix solution (7 mg/ml 
α-cyano-4-hydroxycinnamic acid and 130μg/ml ammonium citrate in 75% ACN) 
via a 25-nl mixing tee (Upchurch Scientific, Oak Harbor, WA) before they were 
spotted onto a 1232-well stainless steel MALDI target plate (AB SCIEX) using a 
Probot Micro Precision Fraction collector (Dionex-LC Packings). 50 fmol of 4700 
Proteomics Analyzer Calibration Mixture 1 (AB SCIEX, Foster City, CA) was 
used for mass calibration. 
2.4 MALDI-TOF/TOF MS 
 
The sample spots were analyzed using a 4800 MALDI TOF/TOF
TM
 
Analyzer (AB SCIEX). MS/MS analysis was achieved with air as collision gas at 
collision energy of 1kV and collision gas pressure of 1X10
-6
Torr. 1000 laser shots 
were accumulated from each sample well and the precursor ions were selected 
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from MS spectra ranging from 920 Da to 3900 Da with a minimum signal to noise 
(S/N) ratio of 40. MS/MS analyses were performed for the seven most abundant 
precursor ions per well. 5000 shots were accumulated for each MS/MS spectrum. 
All MS/MS spectra were searched by the Protein Pilot 
TM 
software v. 2.0.1 
(AB SCIEX, Foster City, CA) for relative quantification and protein identification 
against the International Protein Index (IPI) human database (version 3.72, 
17,2772 sequences) (Kersey et al., 2004). Protein identification and relative 
iTRAQ quantification were performed with the Protein Pilot Software 2.0.1 (AB 
SCIEX) using the Paragon algorithm. The search parameters allowed for cysteine 
modification by methyl methanethiosulfonate, and biological modifications set by 
the algorithm. The detected protein threshold (Unused ProtScore) in the software 
was set to 1.3 to achieve a 95% confidence. The identified proteins were grouped 
by the ProGroup algorithm in the software to minimize redundancy. All protein 
groups reported were based on MS/MS spectra of at least two peptides. No 
identification was based on PMF alone.  
2.5 MS DATA ANALYSIS 
 
The results were exported into Microsoft Excel for data curation. Peptides 
which were unique for a specific protein group were incorporated in the relative 
quantitation by the ProGroup algorithm. Those peptides of low identification 
confidence (<15%), shared MS/MS or no iTRAQ modification were excluded 
from the quantitative analysis. The average ratios for the proteins were calculated 
























xi= log(peptide ratioi), wi=1/%Errori, the weight for the ith observation 
The p values which represents the probability of the observed ratio is 
different than 1 by chance were also reported. 
The geometric mean of the 4 iTRAQ ratios of each pair of cell lines range 
from 0.94 to 1. The standard deviation of log ratios of the 4 iTRAQ ratios of each 
pair of cell lines range from 0.28-0.36. 
An iTRAQ ratio of >1.5 was taken to be a significant change for up-
regulated proteins, and <0.67 for down-regulated proteins. These values represent 
95% confidence (2 standard deviations) based on MS/MS analysis of two 
equivalent protein standards (Tan et al., 2008). Proteins that meet the cutoff value 
must also show consistent changes in both replicate samples, and have iTRAQ 
ratios’ p values <0.05 in at least one of the data set to be considered as 
differentially expressed.  
For Gene Ontology annotations, the protein lists were mapped to their 
associated localizations, biological processes and molecular functions using the 
Software Tool for Researching Annotations of Proteins (STRAP), obtaining the 
respective information from UniProtKB and EBI GOA databases (Bhatia et al., 
2009). The ID list and differentially-expressed protein list were uploaded to the 
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, 
CA) to identify the associated networks based on scores that showed the relevance 
of networks according to p values.  




10 µg of proteins from each gastric cancer cell line lysate was first resolved 
by SDS-PAGE at a constant current of 15 mA/gel in 10% (v/v) polyacrylamide 
gel and then were electroblotted onto a PVDF membrane at a constant voltage of 
100 volt. The membranes were blocked in 5% milk (w/v) in Tris buffered saline 
(TBS-T) with 0.1% Tween 20 (USB, Cleveland) for 2 hours. Primary antibodies 
were used, with dilution factors and incubation times according to the 
manufacturer’s recommendation, in 1% (w/v) milk in TBS-T. Primary antibodies 
used were mouse monoclonal anti-L-caldesmon (1:5000) (BD Biosciences, San 
Jose, CA), mouse monoclonal anti-fascin (1:5000) (Abcam, Cambridge, UK), 
rabbit anti-UCHL1 (1:5000) (Millipore, Marlborough, MA), mouse anti-
tropomyosin (1:1000) (Sigma, St. Louis, MO), and rabbit anti-myosin10 (1:1000) 
(Cell Signaling Technology, Danvers, MA) antibodies. Mouse anti-α-actin 
(1:10,000) (Abcam, Cambridge, UK) and rabbit anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (1:10,000) (Santa Cruz Biotechnology, Santa Cruz, CA) 
were used as loading controls. Secondary antibodies used were HRP- conjugated 
goat anti-rabbit IgG (1:5000) (Pierce, Rockford, IL), HRP-conjugated goat anti-
rabbit IgG (1:5,000) (Santa Cruz Biotechnology, Santa Cruz, CA) and HRP-
conjugated sheep anti-mouse IgG (1:5000) (GE Healthcare, Little Chalfont, 
Buckinghamshire, United Kingdom). The membrane was washed three times with 
TBS-T in between each antibody incubation step. Subsequent visualization was 
performed using the SuperSignal West Dura Extended Duration Substrate (Pierce, 
Rockford, IL) and developed using the Kodak developer and X-ray film, or 
visualized with the ChemiDoc™ MP System (Bio-Rad, Hercules, CA). The 
intensity of the bands was quantified by the Quantity One software (GE 
Healthcare). 
2.7 IMMUNOCYTOCHEMISTRY, TISSUE 
IMMUNOHISTOCHEMISTRY 




The 4 gastric cancer cell lines: AGS, AZ521, FU97 and MKN7 were each 
cultured as described above. The cells were pelleted by centrifuging at 1000 × g 
for 10 min, and fixed in Bouin’s solution. The cell pellets were transferred for 
formalin processing and embedded in paraffin cell, and sectioned at 5 µm 
thickness using a microtome.  
2.7.2 Tissue Immunohistochemistry (IHC) Sample Preparation 
 
The tissue samples from 9 patients admitted to Singapore General Hospital 
between 2004 and 2007 were embedded in paraffin and sectioned for hematoxylin 
and eosin staining. The tumor regions were reviewed and determined by a 
pathologist. 5 µm sections from the tissue blocks were made with a microtome. 
Tissue microarray (TMA) of gastric cancer was constructed with a manual tissue 
arrayer (Beecher instruments, Silver springs, MD). Cylindrical cores of 1 mm 
diameter were taken from tissue blocks from 240 patients admitted to Singapore 
General Hospital between 1998 and 2008, and two cores were taken for each case. 
Among the 240 patients, 37.8% patients were diagnosed in early tumor stage (T1-
T2), while 62.2% were in T3-T4. 25% patients had no lymph node metastasis 
(N0), and 75% had lymph node metastasis (N1-N3). 85.7% patients had no distant 
metastasis (M0), 14.3% had distant metastasis (M1) 
2.7.3 Immunostaining 
 
The cell block and gastric tumor tissue sections were de-waxed using 
xylene and ethanol. Antigen retrieval was performed using Tris-EDTA solution 
(pH = 9) for L-caldesmon, and citrate solution (pH = 6) for fascin with a 
multifunctional microwave histoprocessor (Milestone, Italy) for 10 minutes. H2O2 
solution (Dako, Glostrup, Denmark) was added to the tissue sections for 10 min to 
block endogenous hydrogen peroxidase. Excess reagents were removed from the 
slides by washing with TBS thrice, each for 3 minutes.  
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Mouse monoclonal anti-L-caldesmon (BD Biosciences, San Jose, CA) and 
mouse monoclonal anti-fascin (Abcam, Cambridge, UK) were used as primary 
antibodies at a dilution of 1:400. The slides were incubated with the primary 
antibodies for 1 h and subsequently stained with Dako’s Real EnVision Detection 
Kit (Dako, Glostrup, Denmark) following the manufacturers’ instruction. The 
slides were counterstained with hematoxylin (Merck, Darmstadt, Germany). The 
stained tissue images were scanned and viewed using the ImageScope software 
(Aperio, CA).  
The intensity of the immunocytochemical (ICC) and immunohistochemical 
(IHC) staining and percentage of positive cells were evaluated by a pathologist. 
The staining intensity score was rated as follows: 0: no staining, 1+: weak 
staining, 2+: moderate staining, 3+: strong staining. % positive represents the 
percentage of positively stained tumor cells. Staining index was calculated as the 
sum of intensity scores and the percentage of positively stained cells. Wilcoxon 
signed rank test was used in statistical analysis of paired lymph nodes and 
primary tumors. Fisher’s exact test was used to determine the association between 
the staining index and the tumor clinical features. The software used for statistical 
analysis is GraphPad Prism version 5 (San Diego, CA). 
2.8 SIRNA-MEDIATED CALDESMON KNOCKDOWN 
 
AGS and FU97 cells were seeded into 6-well plates at a density of 3×10
5 
cells per well, and cultured for 24 hours prior to transfection. 10 nM ON-
TARGETplus siRNA SMART pool which contained a mixture of 4 siRNA 
specific for CALD1 gene (Dharmacon Inc., IL) was introduced to the cells by 
transfection using 2.5 µl Lipofectamine™ RNAiMAX Transfection Reagent 
(Invitrogen, Carlsbad, CA) per well. In addition, 10 nM ON-TARGETplus Non-
targeting Control pool (Dharmacon) was transfected to control cells for 
comparison to rule out any off-target effects. 48 hours after transfection, the cells 
were harvested for immunoblotting to confirm the knockdown of CALD1.  
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2.9 REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION 
(RT-PCR) FOR IDENTIFICATION OF CALDESMON ISOFORMS 
2.9.1 RNA Isolation 
 
Total RNA of AGS, AZ521, FU97 and MKN7 cell lines were isolated with 
TRIZOL Reagent (Invitrogen) according to the manufacturer’s instruction. The 
cell pellets were lysed with 1 ml TRIZOL Reagent. 0.2 ml chloroform was added 
to each tube and the phase separation was achieved by centrifuging at 4 °C, 
12,000 g for 15 min. The upper aqueous phase was transferred to a fresh tube and 
the RNA was precipitated with 0.5 ml isopropyl alcohol, and washed with 70% 
ethanol. The extracted RNA was quantified with Nanovue spectrophotometer (GE 
Healthcare). 




III First-Strand Synthesis System (Invitrogen) was used for 
first strand cDNA synthesis according to the manufacturer’s protocol. 2 µg RNA 
was mixed with 1 µl 50 µM oligo(dT)20 primer and 1 µl 10 mM dNTP, and 
incubated at 65 °C for 5 min for denaturing. The sample tube was then placed on 
ice for 1 min. 10 µl cDNA synthesis mix (containing 2 µl 10×RT buffer, 2 µl 0.1 
M DTT, 4 µl 25 mM MgCl2, 1 µl RNaseOUT™  and 1 µl SuperScript III RT) 
were added to the tube and incubated at 50 °C for 50 min. The cDNA synthesis 
reaction was terminated by incubation at 85 °C for 5 min, briefly chilled on ice 
and the RNA was removed by 1 µl RNase H at 37 °C for 20 min.  
2.9.3 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) 
 
Forward and Reverse primers for caldesmon (Table 2.2) (1
st
BASE, 
Singapore) were used to differentiate the isoforms of caldesmon (Figure 2.2) 
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(Okamoto et al., 2000). 2 µl cDNA template was mixed with 10 µM forward and 
reverse primers, 0.3 µl dNTP, 3 µl 5×PCR buffer, 0.075 µl Taq DNA polymerase 
(Invitrogen) and topped up to 15 µl. with H2O. The thermal cycling parameters 
were set as: 95 °C for 30 sec, 60 
0
C for 40 sec, 72 °C for 30 sec for 35 cycles. The 
reaction was terminated at 72 °C for 5 min. β-actin was used as an internal control 
to check the efficiency of cDNA synthesis and PCR amplification. The PCR 





Figure 2.2 The structure of human caldesmon gene consists of at least 14 
exons. The arrows indicate the position of the primers used for PCR amplification 
to identify the isoforms. The six isoforms were shown here. Isoform 1 and 2 are 
h-caldesmons which are expressed in muscle cells. Isoforms 3 and 4 can be 
distinguished from isoforms 5 and 6 by primer P1 or P1’. The difference between 
isoforms 3 and 4, isoform 5 and 6 is the presence of exon 4(78 bp), which can be 
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Table 2.2 The list of primers that were used to differentiate the 





2.10 STABLE OVER-EXPRESSION OF CALDESMON 
 
Stable over-expression of caldesmon was achieved in AZ521 cells which 
have low intrinsic expression level of caldesmon. 3×10
4
 cells were seeded in a 24-
well plate for 24 h. 800 ng of an expression clone encoding human caldesmon 1 
transcript variant 3 (also containing puromycin resistance gene) (Genecopoeia, 
Rockville, MD) was transfected using 2 µl Lipofectamine™ 2000 Transfection 
Reagent (Invitrogen). After 24 h incubation, the cells were trypsinized and seeded 
in 1:10 dilution with 1 µg/ml puromycin (Sigma, St. Louis, MO) as the selection 
reagent. Mock transfection of the empty vector was done in parallel as the 
negative control. The culturing media was changed every 2-3 days with fresh 
puromycin. After 2-3 weeks, most of the cells without stable gene integration died 
and those with stable gene integration grew as individual colonies. These colonies 
were picked with brief trypsinization and were serial diluted in 96-well plate to 
obtain single cell per well. Each single cell-generated colony was maintained in 
puromycin-containing media and their expression levels of caldesmon were 
checked by Western blotting.  
2.11 CELL ASSAYS 




cells were seeded per well in a 24-well plate (Day 0). After 24, 48 
and 72 h, 5 mg/ml of 20 µl 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide (MTT) (Invitrogen) dissolved in phosphate buffer saline were added to 
the wells and incubated at 37 °C for 2 h. The insoluble purple color formazan 
formed from the reduction of tetrazolium MTT by viable cells were solubilized by 
200 µl dimethyl sulfoxide (Sigma, St. Louis, MO) and the OD were recorded at 
550 nm.  
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2.11.2 Wound Healing Assay 
 
Wound healing assays were performed with ibidi silicone-insert (ibidi 
GmbH, Martinsried, Germany). 7×10
5 
cells were seeded in both reservoirs of the 
insert for 24 h. Upon removal of the insert, the closure of the gap was monitored 
under a light microscope. Triplicate experiments were performed. The images 
were taken with a 10×objective lens. 
2.11.3 Transwell Migration Assay and Matrigel Invasion Assay 
 
Transwell migration assays were carried out using 8.0 micron PET cell 
culture insert (BD Biosciences, San Jose, CA) coated with 10 µg/ml fibronectin 
(Sigma, St. Louis, MO) overnight. 3×10
4 
cells in media containing 10% FBS were 
seeded into each insert. Invasion assays were performed with the BioCoat 
Matrigel Invasion chambers (BD Biosciences, San Jose, CA) using 5×10
4 
cells. 
After 48 h, the cells that had not migrated across the insert pores were removed 
with a cotton swab. The cells that had migrated through the pores and adhered to 
the other side of the insert were fixed with 3% paraformaldehyde and stained with 
crystal violet. The migrated cells were quantified by dissolving the crystal violet 
dye intake in 1% SDS, and the absorbance was measured at 595 nm. The images 
were captured with a light microscope and were processed with ImageScope 
software (Aperio, CA). The experiments were repeated 3 times. 
2.11.4 Cell Attachment Assay 
 
Cell attachment assay was performed in 96-well plate. The wells were 
coated with fibronectin for 1 h at 37 °C, followed by blocking with 0.5% BSA in 
medium for 1 h. The wells were then washed with 0.1% BSA in medium. 2×10
4
 
Cells were seeded into the wells for 35 min and the non-attached cells were 
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washed away by phosphate buffer saline (PBS). The cells were fixed with 3% 






2.12.1 Caldesmon Co-Immunoprecipitation 
 
The co-immunoprecipitation experiment was performed with Classic IP kit 
(Pierce, Rockford, IL) according to the manufacturer’s instruction. FU97 cells 
were grown in T175 flask till confluent. The cells were washed twice with cold 
phosphate buffer saline (PBS) and a cell scrapper was used to detach the cells. 
The cells were pelleted at 1,000 g for 5 min. 500 µl IP lysis/wash buffer (0.025 M 
Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP-40, 5% glycerol, pH 7.4)with 2.5 µl 
Halt protease inhibitor cocktail (Pierce, Rockford, IL) was used to lyse the cells 
on ice for 10 min. The lysate was centrifuged at 13,000 g, 4 °C for 30 min and the 
protein concentration in the supernatant was determined by Coomassie Plus 
Protein Assay reagent kit (Pierce, Rockford, IL). 1 mg of the protein lysates was 
incubated with 2.5 µg anti-caldesmon antibody (BD Biosciences, San Jose, CA) 
in a total volume of 400 µl overnight with gentle end-over-end mixing. 
After the incubation step, 20 µl protein A/G agarose beads were washed 
twice with 100 µl IP lysis/wash buffer in a spin column, and the lysates were 
added to the beads and incubated for 2 h with gentle end-over-end mixing for the 
immunocomplex to bind to the agarose beads. The beads were washed thrice with 
200 µl IP lysis/wash buffer and once with 100 µl conditioning buffer, before the 
immunocomplex was eluted thrice with 20 µl elution buffer. The low pH of the 
eluate was neutralized with 0.5 µl 1M Tris, pH 9.5. A control experiment was 
performed with an equal amount of lysates incubating with the agarose beads only, 
and washed and eluted as described above. The presence of caldesmon in the 
eluate was checked with Western blotting. 




8 µl of the lysates, eluates and control eluate from IP were resolved by 
SDS-PAGE at a constant current of 15 mA/gel in 10% (v/v) polyacrylamide gel. 
The gel was silver-stained based on a modified Vorum protocol (Mortz et al., 
2001). The gel was fixed in 50% (v/v) methanol, 12% (v/v) aceticacid and 0.05% 
(v/v) formalin for 2 h, followed by washing thrice in 35% (v/v) ethanol, each 20 
min. The gel was then sensitized in 0.02% (w/v) sodium thiosulphate for 2 min. 
The gel was rinsed thrice with water for 5 min, followed by incubation in 0.2% 
(w/v) silver nitrate and 0.076% (v/v) formalin for 20 min. The gel was washed 
twice with water, each 1 min, then developed in 6% (w/v) sodium carbonate, 
0.004% (w/v) sodium thiosulphate with 0.05% (v/v) formalin. Upon reaching the 
desired density, the gel was incubated for 20 min in 1.46% (w/v) sodium 
ethylenediaminetetraacetic acid (EDTA) to stop the development. Lastly, the gel 
was washed thrice with water, 5 min each time. Every step was conducted with 
constant shaking.  
2.12.3 In-Gel Tryptic Digestion 
 
The protein bands of interest were excised from the silver stained gel. Each 
band was soaked in 150 μl of 50% HPLC grade acetonitrile (ACN) 
(ThermoScientific, Bremen, Germany) with 2.5 mM ammonium bicarbonate 
(NH4HCO3) (Sigma) washing buffer for 24 h at 4 °C. Fresh washing buffer of 150 
μl of 50% ACN, 2.5 mM NH4HCO3 was added and the bands were incubated at 
37 °C for 10 min. The bands were vacuum dried for 10 min before 20 μl of 10 
mM dithiothreitol (DTT) (Bio-Rad, Hercules, CA) in 100 mM NH4HCO3 was 
added for protein reduction at 56 °C for 1 h. The DTT solution was then removed 
and the bands were incubated with 20 μl of 55 mM iodoacetamide (IAA) (Fluka, 
Buchs, Switzerland)) in 100 mM NH4HCO3 for 45 min at room temperature in the 
dark. The bands were then soaked in 100 mM NH4HCO3 at 37 °C for 10min, 
followed by incubation in 100 μl ACN for 10 min at room temperature. These two 
steps were repeated. The bands were then vacuum dried. 0.1 μg of sequence grade 
modified trypsin (Promega, Madison, WI) was added to each band and 
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trypsinization was performed at 37 °C for 16 h. After that, the peptide extraction 
was further enhanced by the addition of 10 μl of 0.1% formic acid (FA) (Fluka) in 
50% ACN to each band and the tubes were sonicated for 20 min in an ultrasonic 
water bath. 
The digested samples were desalted with Sep-Pak tC18 µElution Plate 
(Waters, Milford, MA) according to the manufacturer’s instruction. The plate was 
activated with 400 µl 100% ACN with 0.05% formic acid twice with a full 
vacuum pressure by a vacuum manifold, followed by equilibration with 400 µl 2% 
(v/v) ACN with 0.05% FA in H2O twice. The digested samples were topped up to 
250 µl with 2% (v/v) ACN with 0.05% FA in H2O and loaded to the plate with 
half vacuum pressure for binding. The unbound fractions was washed away with 
200 µl 2% (v/v) ACN with 0.05% FA in H2O. The peptides were eluted by 100 µl 
80% ACN with 0.05% FA in H2O thrice. The eluate was vacuum dried and 
redissolved in 10 µl 2% (v/v) ACN with 0.05% FA in H2O for mass spectrometry 
analysis. 
2 l sample was loaded onto ChromXP C18-CL, 3 µm 120 A trap column 
(Eksigent, Dublin, CA) and eluted on an analytical column (Eksigent) with 
increased organic phase gradient at a flow rate of 300 nl/min on an Eksigent 
nanoLC Ultra and ChiPLC-nanoflex system. The MS spectra were acquired on a 
TripleTOF 5600 system (AB SCIEX) across a mass range of 400-1250 m/z in 
high resolution mode (>30000). A maximum of 10 precursors per cycle were 
chosen for fragmentation from each MS spectrum. Tandem mass spectra were 
performed in high sensitivity mode (resolution >15000). All MS/MS spectra were 
searched by the Protein Pilot 
TM 
software v. 4.0 (AB SCIEX) against UniProt 






CHAPTER 3 RESULTS 
3.1 ITRAQ ANALYSIS OF METASTATIC VERSUS PRIMARY GASTRIC 
CANCER CELL PROTEOMES 
 
From the iTRAQ results, a total of 641 proteins were identified with 95% 
confidence. To obtain the Gene Ontology information (The Gene Ontology 
Consortium., 2000) of these proteins, we used the Software Tool for Researching 
Annotations of Proteins (STRAP), an open‐source C# application which annotates 
gene functions based on gene ontology (GO) terms associated with Uniprot 
protein IDs (Bhatia, 2009). The proteins identified from the iTRAQ results 
covered a wide range of cellular locations: 24% from nucleus, 21% from 
cytoplasm, 7% from mitochondria, 7% from cytoskeleton and 8% from plasma 
membrane (Figure 3.1).  
For each of the proteins identified, the relative expressions between well/ 
moderate-differentiated metastatic (MKN7) versus primary cell line (AGS), and 
poorly-differentiated metastatic (AZ521) versus primary cell line (FU97) were 
represented by 8 iTRAQ ratios. With cutoff value of 1.5-fold applied, the proteins 
were considered to be up-regulated when 6 out of 8 iTRAQ ratios were above 1.5, 
and at least one ratio with p<0.05 and down-regulated when 6 of the 8 iTRAQ 
ratios < 0.67, and at least one ratio has p<0.05. The list of these differentially-
expressed proteins (19 up- and 33 down-regulated) was shown in Table 3.1. Up-
regulation of proteins involved in the transcriptional regulation and translational 
regulation were observed in the metastatic cell lines. The up-regulation of proteins 
involved in glycolysis (LDHA) and down-regulation of proteins in tricarboxylic 
acid cycle (IDH1, FH, SDHA) may be associated with the cancer cells’ increasing 
demand for energy and switching from normal oxidative phosphorylation to 
glycolysis during metastasis progression (Pani et al., 2010). 
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The analysis of these 52 differentially-expressed proteins using the 
Ingenuity Pathway Analysis (IPA) software showed that the top networks were 
related to cell death, cellular movement, cell growth and proliferation. The top-
ranking network, with 16 of the regulated proteins mapped to it, was presented in 
Figure 3.2. Several proteins associated with this network have been reported in 
previous studies to predict cancer metastasis. For example, high expression level 
of aldehyde dehydrogenase ALDH1A3 has been proposed to predict breast cancer 
metastasis (Marcato et al., 2011). Leukocyte elastase inhibitor SERPINB1, a 
matrix metalloproteinase inhibitor, was found to have lower expression level in 
tumors as compared to normal tissues (Chen et al., 2007). In addition, it was 
noted that cell motility-related cytoskeleton proteins, such as caldesmon, were 






Figure 3.1 Gene Ontology classification of the cellular component of total 



























Figure 3.2 Top network for the differentially expressed proteins in gastric cancer metastasis. Green: down-regulated proteins, 


















40.03 EEF1A1 Elongation factor 1-alpha 1 
Protein biosynthesis, Transcription 
regulation 
1.49 1.69 0 
IPI00789435.
2 
6 EEF1D Elongation factor 1-delta isoform 3 2.53 1.95 0.02 
IPI00738381.
2 
17.88 EEF1G Elongation factor 1-gamma 1.60 1.63 0 
IPI00946642.
1 
4.77 EIF5A2 Eukaryotic translation initiation 
factor 5A2 
1.46 1.84 0 
IPI00299573.
12 
2.8 RPL7A 60S ribosomal protein L7a 
Structural constituent of ribosome, 
RNA binding, Translation 
1.79 2.93 0.002 
IPI00027270.
1 
2.11 RPL26 60S ribosomal protein L26 1.89 3.76 0.0036 
IPI00927658.
1 
2.17 RPL32 Ribosomal protein L32 1.72 3.16 0.006 
IPI00794894.
1 





Heat shock protein HSP 90-beta  Molecular chaperone,  
Stress response 
1.66 1.87 0 
IPI00026663.
2 
7.66 ALDH1A3 Aldehyde dehydrogenase family 1 
member A3  
Catalyze aldehyde + NAD(P)+ to 
carboxylate + NAD(P)H. 
7.71 4.92 0.0006 
IPI00218414.
5 
2.01 CA2 Carbonic anhydrase 2  Catalyze H2CO3 = CO2 + H2O 1.83 8.86 0.06 
IPI00947127.
1 
18.31 LDHA Lactate dehydrogenase A chain 
isoform 3  
Glycolysis, (S)-lactate + NAD+ to 
pyruvate + NADH. 
1.69 1.89 0 
IPI00218918.
5 
16.15 ANXA1 Annexin A1  
Calcium ion binding 





2 ANXA5 Annexin A5 2.28 2.25 0.01 
IPI00747810.
2 
9.08 FSCN1 Fascin Actin filament bundle assembly, 
Cell migration, invasion 
5.21 3.91 0.0023 
IPI00790503.
3 
2.22 MYH10 Isoform 3 of Myosin-10  Actin filament-based movement 3.18 1.74 0.027 
IPI00007402.
3 
10 IPO7 Importin-7  Nuclear protein import 1.80 3.40 0.02 
IPI00018352.
1 
5.24 UCHL1 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1  
Ubl conjugation pathway 5.01 3.40 0.015 
IPI00023860.
1 
4.59 NAP1L1 Nucleosome assembly protein 1-like 
1  
Modulating chromatin formation, 
regulation of cell proliferation 
1.40 1.75 0.004 














6.01 ALDH3A2 Isoform 2 of Fatty aldehyde 
dehydrogenase 
Catalyzes the oxidation of long-
chain aliphatic aldehydes to fatty 
acids 
0.47 0.31 0.03 
IPI00219757.
13 
8.74 GSTP1 Glutathione S-transferase P Conjugation of reduced glutathione 
to hydrophobic electrophiles 





Cytochrome P450 reductase Catalyze NADPH + oxidized 
hemoprotein to NADP
+
 +  reduced 
hemoprotein. 
0.59 0.39 0.0003 
IPI00910902.
1 
10 NQO1  cDNA FLJ50573, highly similar to 
Homo sapiens NAD(P)H 
dehydrogenase, quinone 1 (NQO1), 
transcript variant 3, mRNA 
Catalyze NAD(P)H + a quinone = 
NAD(P)+ + a hydroquinone- 
0.20 0.10 0.0046 
IPI00939560.
1 
7.55 TXNDC5 MUTED thioredoxin domain-
containing protein 5 isoform 3 
Cell redox homeostasis 0.50 0.51 0.0082 
IPI00004669.
1 




0.74 0.40 0.0003 
IPI00027223.
2 
5.45 IDH1 Isocitrate dehydrogenase [NADP] 
cytoplasmic 
Tricarboxylic acid cycle 





2 FH Isoform Cytoplasmic of 
Fumaratehydratase, mitochondrial 
0.63 0.41 0.02 
IPI00217143.
3 
2.15 SDHA SDHA protein 0.44 0.35 0.015 
IPI00921173.
1 
4 SUCLG1 SUCLG1 protein 0.72 0.61 0.0052 
IPI00024993.
4 
2 ECHS1 Enoyl-CoA hydratase, 
mitochondrial 
Fatty acid metabolism 0.43 0.51 0 
IPI00218568.
7 
4.32 PCBD1 Pterin-4-alpha-carbinolamine 
dehydratase 
Transcription regulation 0.25 0.55 0.02 
IPI00016703.
2 
4.03 DHCR24 24-dehydrocholesterol reductase Cholesterol metabolism 0.51 0.25 0.049 
IPI00643801.
1 
3.67 CTSA Cathepsin A Lysosome function 0.67 0.40 0.0042 
IPI00022334.
1 
3.3 OAT Ornithine aminotransferase, 
mitochondrial 
Amino-acid biosynthesis 0.49 0.49 0.0012 
IPI00293303.
1 










Serpin H1 Collagen biosynthetic process 0.77 0.35 0 
IPI00872780.
1 
3 ANXA4 Annexin A4 
Calcium-binding protein 
0.41 0.13 0.013 
IPI00295542.
5 
2.06 NUCB1 Nucleobindin-1 0.63 0.55 0.065 
IPI00554648.
3 
42.5 KRT8 Keratin, type II cytoskeletal 8 Intermediate filament 0.57 0.21 0 
IPI00014516.
1 
4.07 CALD1 Isoform 1 of Caldesmon Actin binding 0.33 0.18 0.0006 
IPI00010951.
2 
3.89 EPPK1 Epiplakin Cytoskeleton protein 0.26 0.61 0.015 






22.06 TUFM Tu translation elongation factor, 
mitochondrial precursor Protein biosynthesis 
0.72 0.60 0 
IPI00017283.
2 
10.5 IARS2 Isoleucyl-tRNAsynthetase, 
mitochondrial 
0.64 0.41 0.0001 
IPI00642984.
2 
6.19 BCAP31 B-cell receptor-associated protein 31 
isoform a 
Protein transport 0.78 0.45 0.0005 
IPI00292135.
1 
6.18 LBR Lamin-B receptor Nuclear envelope inner membrane 
protein 
0.65 0.45 0.0021 
IPI00922055.
1 
5.5 DBI Diazepam binding inhibitor, splice 
form 1G 
Transport  0.63 0.47 0.0013 
IPI00646182.
5 
18.21 ATP1A1 Sodium/potassium-transporting 
ATPase subunit alpha-1 isoform c 
Ion transport 
0.73 0.57 0 
IPI00010896.
3 
2.83 CLIC1 Chloride intracellular channel 
protein 1 
0.64 0.64 0.03 
IPI00924436.
1 
2.14 HSPB1 Heat shock 27kDa protein 1 Stress resistance and actin 
organization 
0.21 0.48 0.04 
IPI00908889.
1 
4.62 PITRM1 cDNA FLJ54065, moderately 
similar to 
Musmusculuspitrilysinmetallepetida
se 1 (Pitrm1), mRNA 
Mitochondria ATP-independent 
protease 
0.43 0.44 0.04 
 
Table 3.1 Differentially expressed proteins, their accession numbers, gene symbols identified from the iTRAQ 
study. The relative expression of each protein was based on the ratio of the respective iTRAQ labels. The protein functions were 
extracted from the Uniprot database. 
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3.2 VERIFICATION OF SELECTED TARGETS WITH WESTERN 
BLOTTING 
 
Several of the differentially-expressed proteins found in this iTRAQ study 
have been reported to be perturbed in other cancer types. The up-regulation of 
fascin in non-small cell lung cancer is associated with cancer malignancy (Zhao et 
al., 2010). UCHL1 plays a key role in regulating invasion and renal cell 
carcinoma metastasis (Kim et al., 2009; Seliger et al., 2007). Caldesmon binds to 
actin and has been found in the invasion front of cancer cells, while ectopic 
expression of caldesmon in transformed fibroblast cells reduces cancer cell 
invasiveness (Yoshio et al., 2007). In our iTRAQ data, fascin expression has been 
found to be high in metastasis-derived MKN7 and AZ521 compared to their 
primary counterparts AGS and FU97.  UCHL1 is overexpressed in MKN7 and 
AZ521 compared to in AGS and FU97. Caldesmon has been found to be down-
regulated in MKN7 and AZ521cells as compared to the primary cell counterpart 
AGS and FU97. 
The differential expressions of these 3 proteins were verified in AGS, 
FU97, MKN7, and AZ521 cell lysates with western blotting (Figure 3.3). The 
Western blotting results were quantified with densitometry and were in agreement 
with the iTRAQ results. 
Caldesmon and fascin are of special interest as they are both actin 
cytoskeleton associated proteins that have been reported to be involved in cell 
migration and invasion (Vignjevic et al., 2007; Yoshio et al., 2007). To study the 
expression level of caldesmon and fascin, we analyzed a panel of gastric cancer 
cell lines from primary cancer (AGS, FU97) as well as gastric cancer cell lines 
isolated from various metastasis status (lymph node (MKN7, AZ521), liver 
(MKN74, N87) and ascites (SNU16, YCC1,YCC2, YCC3, YCC9)) with Western 
blotting. It was observed that caldesmon expressions were higher in primary-
cancer derived cell lines compared to lymph node and liver metastasis-derived 
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gastric cancer cell lines. Caldesmon expressions are either low or not detected in 
the ascites-derived cell lines. Fascin expressions are low in primary cancer cell 
lines AGS and FU97, and high in lymph node and liver metastasis-derived gastric 
cancer cell lines (MKN7, AZ521, MKN74, N87), and in 2 out of 5 ascites-derived 
gastric cancer cell lines (YCC2, YCC9) (Figure 3.4). The lower expression of 























Figure 3.3 Analysis of expression levels of 3 target proteins by (A) Western 
blotting and (B) quantitation with densitometry in 4 gastric cell lines. Actin 
and GAPDH were used as loading controls. Caldesmon was down-regulated; 
fascin and UCHL1 were up-regulated in metastatic cell lines. Densitometry 




























Figure 3.4 Western blotting showed the expression levels of caldesmon and 
fascin in a panel of 11 gastric cancer cell lines. Actin was used as a loading 
control. Caldesmon level was reduced in lymph node metastasis-derived MKN7 
and AZ521, liver metastasis-derived MKN74 and N87, and ascites-derived 
SNU16, YCC1, YCC2, YCC3 and YCC9. Fascin expressions were low in AGS 
and FU97 and high in 6 out of 9 metastatic-derived gastric cancer cell lines 



















3.3 VERIFICATION OF CALDESMON AND FASCIN EXPRESSION 
WITH IMMUNOCYTOCHEMISTRY 
 
Immunostaining of caldesmon and fascin in the 4 gastric cancer cell lines 
was carried out. The nuclei were stained blue by hematoxylin, while the target 
proteins were stained brown. Combining the intensity score and percentage of 
positively-stained cells, AGS and FU97 have stronger caldesmon expression 
compared to MKN7 and AZ521, and weaker fascin expression compared to 
MKN7 and AZ521; caldesmon and fascin were found to be localized in the 
cytoplasm of the cell (Figure 3.5). The results are in accord with our findings 
from iTRAQ and western blotting. Our results show that AZ521 cell line was 
partially stained. This could be due to a variably expression of caldesmon during a 
dynamic process of tumor heterogeneity and clonal expansion, and assessment on 
tissue alone may be restrictive. In future work, we can look for this marker in the 












Figure 3.5 (A) Immunocytochemical staining of caldesmon and fascin in cell 
blocks of 4 gastric cancer cell lines. 
(B)The intensity scores and the percentages of positive stained cells were 
shown in the table. The intensity was rated from 0 to 3+; 0 represents no 
expression, and 3+ represents the strongest expression. Both intensity and % of 
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Caldesmon immunostaining Fascin immunostaining 
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3.4 CALDESMON AND FASCIN EXPRESSION IN PAIRED LYMPH 
NODE METASTASIS AND PRIMARY GASTRIC CANCER TISSUES 
 
We further examined the expression of caldesmon and fascin in gastric 
cancer tissues using immunohistochemical staining of tissues from 9 gastric 
cancer patients with matched primary and lymph node metastasis. As shown in 
Figure 3.6, caldesmon staining is high in the primary cancer cells, but decreases in 
tumor cells from metastatic lymph nodes. Comparing the staining index of 9 cases 
of lymph node metastasized tissues with matched primary cancer tissues revealed 
that caldesmon expression is decreased in the former (p=0.037) (Figure 3.7).  
Strong staining of fascin was observed in lymph node metastasized cancer 
cells, compared to very low intensity of fascin in the primary tumors (Figure 3.8). 
The IHC staining index of 9 cases of lymph node metastasized tissues with 
matched primary cancer tissues revealed that fascin expression is increased in 
tumor cells of lymph node metastasized tissues (p=0.0071) (Figure 3.9). These 
results supported our iTRAQ findings which showed a down-regulation of 
caldesmon and up-regulation of fascin and as the gastric tumor metastasized to 
lymph node. In normal gastric tissues, the expression of fascin and caldesmon 
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Figure 3.6(A) Immunohistochemistry of caldesmon in paired primary gastric 
tumor and lymph node metastasized tissues. (a) signet ring carcinoma primary 
tumor, (b) signet ring carcinoma lymph node metastasis, (c) poorly-differentiated 
gastric cancer primary tumor, (d) poorly-differentiated gastric cancer lymph node 
metastasis, (e) well-differentiated gastric cancer primary tumor, (f) well-
differentiated gastric cancer lymph node metastasis.  
(B) The intensity score and the percentages of the positive stained cells were 
shown in the table. 
 
  
Caldesmon Intensity score Primary tumor lymph node metastasized tissue 
 a) 2+, 80% positive b) 1+, 10% positive 
 c) 2+. 40% positive d) 0 












Figure 3.7 Staining index of caldesmon in lymph node metastasis was 
significantly decreased as compared to primary tumor. N=9. Wilcoxon signed 







    
    
    
(B) 
Figure 3.8(A) Immunohistochemistry of fascin in paired primary gastric 
tumor and lymph node metastasized tissues. (a) signet ring carcinoma primary 
tumor, (b) signet ring carcinoma lymph node metastasis, (c) poorly-differentiated 
gastric cancer primary tumor, (d) poorly-differentiated gastric cancer lymph node 
metastasis, (e) well-differentiated gastric cancer primary tumor, (f) well-
differentiated gastric cancer lymph node metastasis.  
(B)The intensity score and the percentages of the positive stained cells were 
shown in the table. 
 
  
Fascin Intensity score Primary tumor lymph node metastasized tissue 
 a) 0 b) 2+, 40% positive 
 c) 0 d) 3+, 30% positive 













Figure 3.9 Staining index of fascin in lymph node metastasis was significantly 






3.5 TISSUE MICROARRAY ANALYSIS OF CALDESMON AND FASCIN 
EXPRESSION 
 
Tissue microarrays (TMA) from gastric cancer tissues of 240 patients were 
constructed. The clinical features of these cases were summarized in Table 3.2. 
The tissue microarrays were subject to immunohistochemical analysis for 
caldesmon and fascin expression. Analysis of the TMA staining showed that the 
increased in fascin expression correlated with advanced serosal invasion and 
lymph node metastasis (Table 3.3). Survival analysis showed that in 
well/moderately-differentiated gastric cancer patients, those with fascin-negative 
tumors had a better clinical outcome than those with fascin-positive tumors 
(p=0.043) (Figure 3.10). 
However, as caldesmon expression was decreased in tumor cells, we found 
only 14 cases of caldesmon expressed in tumor cells. In contrast, the expression 
of caldesmon in the tumor stroma and pericellular matrix was relatively high, and 
an increased pericellular expression of caldesmon was found to be associated with 




Clinical features  Number 
Mean age (range, years)  65.2± 12.0 (27-91 years)  
Gender (male/female)  148/91 (61.9%/38.1%) 




Poorly-differentiated 122 (51.9%) 
Mixed 20 (8.5%)  
Serosal invasion 
absent (T1-T2) 
present (T3-T4)  
 
84 (37.8%) 
138 (62.2%)  
Lymph node metastasis 
absent (N0) 
present (N1-N3)  
 
55 (25%) 
165 (75%)  
Distant metastasis 
absent (M0) 
present (M1)  
 
174 (85.7%) 
29 (14.3%)  
 
Table 3.2 Clinical features of tumor tissues used in the TMA study.  
The patients’ ages ranged from 27-91 years with a median age of 65.2 year. 61.9% 
were male and 38.1% female. Well/moderately differentiated subtypes consisted 
of 39.6%, poorly-differentiated 51.9% and mixed histology 8.5%. 37.8% patients 
have early tumor stage (T1-T2), 62.2% were in T3-T4. 25% patients had no 
lymph node metastasis, 75% had lymph node metastasis (N1-N3). 85.7% patients 

















absent(T1-T2)  61(72.6%)  23(27.4%)  
p=0.0315*  present(T3-T4)  79(58.0%)  57(42.0%)  
Lymph Node Metastasis   
absent(N0)  40(72.7%)  15(27.3%)  
















absent(T1-T2)  53(63.1%)  31(36.9%)  
p=0.0264 *  
present(T3-T4)  65(47.1%)  73(52.9%)  
 
Table 3.3 Increased fascin staining index was correlated with 
serosal invasion and lymph node metastasis, and increased 
caldesmon pericellular staining index was associated with serosal 
invasion only.  The Statistical test used was Fisher’s exact test. Only 27.4% of 
the patients without tumor serosal invasion (T1-T2) had positive fascin IHC 
staining in the tumor cells, while 42% of the patients with tumor serosal invasion 
(T3-T4) had positive fascin stainings. Similarly, only 27.3% of the patients with 
no lymph node metastasis had positive stainings for fascin in the tumors, while 
46.4% of the patients with lymph node metastasis had positive stainings of fascin. 
For caldesmon in the pericellular space of tumor, 36.9% of the patients without 
tumor serosal invasion had positive stainings, while 52.9% of the patients with 







Figure 3.10 Cumulative survival curves in patients with well/moderately-
differentiated gastric cancer. Patients with fascin-negative tumors had a better 
clinical outcome than those with fascin-positive tumors. Survival curves were 
plotted with the method of Kaplan and Meier. Statistical difference between two 







3.6 KNOCKDOWN OF CALDESMON EXPRESSION WITH RNA 
INTERFERENCE 
 
We have discovered that an increase in fascin expression in gastric cancer 
metastasis-derived cell lines and this increasing trend was associated with gastric 
cancer serosal invasion and lymph node metastasis. Fascin promoted cancer cell 
migration and invasion and immunohistochemical studies found that the 
expression of fascin in gastric cancer was associated with metastasis (Tan et al., 
2013). Our findings on fascin corroborated with the current understanding. A 
decreased caldesmon expression in gastric cancer lymph node metastasis derived 
cell lines was also observed. The association of caldesmon expression and gastric 
cancer unveiled by our proteomics study was novel, and functional studies were 
therefore performed to elucidate caldesmon’s role in gastric metastasis. 
We performed knockdown of caldesmon with siRNA in gastric cancer cells, 
and evaluated the migration and invasion behavior of the cancer cell. Caldesmon 
expression was successfully reduced after 48 hours of transfection with 
caldesmon-specific siRNA in AGS and FU97 cells and the knockdown effect 
remained till 96 hours after transfection (Figure 3.11). The growth rates of 
caldesmon knockdown cells were not significantly different from the control cells 
(Figure 3.12). Using wound healing assays, we observed a faster closure of 
scratch wound in the caldesmon knockdown AGS cells and FU97 cells as 
compared to the control cells (Figure 3.13). With transwell migration assay, we 
observed a significant increase in cell migration of the caldesmon knock-down 
cells (Figure 3.14). Using Matrigel invasion assay which mimicked tumor cells’ 
degradation of the basement membrane (Albini & Benelli, 2007), an increased 
number of caldesmon knockdown tumor cells were observed invading through the 
Matrigel matrix as compared to the control cells (Figure 3.15). These findings 
from the cell assays thus proved that caldesmon played a role in suppressing 









Figure 3.11 Western blot showed a decreased caldesmon protein level in AGS 
and FU97 cells upon transfection till 96 hours. Ctrl: control non-target siRNA 





Figure 3.12 MTT assay assessing cell survival 48 hours after siRNA 
transfection showed no growth difference between caldesmon siRNA-transfected 



























































   
   
 
 
   
   
Figure 3.13 Wound healing assays showed within 8 hours, caldesmon siRNA-
transfected AGS cells closed the gap faster than control cells. Wound healing 
assays showed within 24 hours, caldesmon siRNA-transfected FU97 cells closed 
the gap faster than control cells. 
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Figure 3.14 Transwell migration assay of AGS cells and FU97 cells showed 
an increased migration in caldesmon knock-down cells. Quantitation of 
migrated cells compared to control cells showed a significant increase in 
migration of caldesmon siRNA transfected AGS and FU97 cells (**, p<0.01, 
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Figure 3.15 Matrigel invasion assay of AGS and FU97 cell lines with 
caldesmon knockdown. Caldesmon siRNA transfected AGS cells have 
significantly increased invasion as compared to the control cells (*, p<0.05, n=4). 
Matrigel invasion assay showed an increased invasion in caldesmon siRNA 
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3.7 REVERSE-TRANSCRIPTION PCR IDENTIFIED CALDESMON 
ISOFORM 3 AS THE UBIQUITOUS EXPRESSED ISOFORM 
 
Two high-molecular weight caldesmon (h-Cald) isoforms (expressed in 
muscle cells) and four low-molecular weight caldesmon (l-Cald) isoforms 
expressed by alternative splicing have been identified in various cell types (Figure 
2.2) (Okamoto et al., 2000). Western blotting results revealed that the 4 gastric 
cancer cell lines (AGS, FU97, MKN7, AZ521) expressed l-Cald protein which 
was present as a band at 75 kDa (Figure 3.3). In order to determine the transcript 
variants of caldesmon expressed in the gastric cancer cell lines, we isolated RNA 
from the 4 gastric cancer cell lines, reverse-transcribed them into cDNA and 
identified the transcript variants using the isoform-specific primers. We first 
checked the presence of exon 1/exon1’ with the RNA extracts from the four 
gastric cancer cell lines. Both exon1 and exon1’ -specific forward primers yielded 
amplified products together with exon5-specific reverse primer (Figure 3.16). 
Isoform 3, 4, 5, and 6 were all likely to be present in the 4 cell lines. We further 
checked exon 4’s presence with exon 4-specific reverse primer (P4) together with 
exon1- and exon1’-specific forward primer P1, P1’, respectively. As shown in 
Figure 3.17, exon1’ -specific forward primers yielded amplified products when 
combined with exon4-specific reverse primer with RNA isolated from AGS. Both 
exon 1- and exon1’-specific primer yielded amplified products combined with 
reverse primer P4 (exon4-specific) in the other 3 cell lines. Thus it can be inferred 
that caldesmon isoform 3 (NM_033157.3, cald1 transcript variant 3) was present 
in AGS, whereas both isoform 3 and 5 were present in the other 3 cell lines. 












Figure 3.16 RT-PCR amplified products resolved by 1% agarose gel. Both 
exon1 and exon1’ -specific forward primers yielded amplified products together 
with exon5-specific reverse primer. Isoform 3,4,5,6 were all likely to be present in 
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Figure 3.17 RT-PCR amplified products from 4 cell lines resolved by 1% 
agarose gel. Exon1’ -specific forward primers yielded amplified products 
together with exon4-specific reverse primer with AGS RNA isolates. Both exon 
1- and exon1’-specific primer yielded amplified products combined with reverse 
primer P4 (exon4-specific) with FU97, AZ521 and MKN7 RNA isolates. Isoform 
3 was present in AGS, whereas both isoform 3 and 5 were present in the other 3 




































































3.8 STABLE OVER-EXPRESSION OF CALDESMON IN AZ521 CELL 
LINE 
 
To further study the function of caldesmon in cancer metastasis, a cell line 
that stably over-expresses caldesmon was generated using the AZ521 cell line 
which has low intrinsic level of caldesmon (Figure 3.18). There is no difference in 
growth rate between caldesmon over-expressing cells and the control cells (Figure 
3.19). We assessed the cell migration ability using the wound healing assay, and 
found AZ521 cells that over-expressed caldesmon closed the wound slower 
compared to the control cells (Figure 3.20). Using transwell cell migration assays, 
it was observed that caldesmon over-expression led to decreased cell migration 
(Figure 3.21A). A reduction in cell invasion as shown by Matrigel invasion assay 
(Figure 3.21B) was also noticed in the cells that over-expressed caldesmon. 
Caldesmon over-expressed AZ521 cells adhere stronger as compared to the 
control cells (Figure 3.21C). Our functional assays suggested that the observed 
differences in migration and invasion were due to caldesmon over-expression, and 
it is proposed that caldesmon, as an integral part of the cytoskeleton, may enhance 










Figure 3.18 Western blotting showed AZ521 cell line that over-expressed 




Figure 3.19 MTT survival assay showed that over 3 days, the growth rate of 
















   
   
 
Figure 3.20 Wound healing assay showed that caldesmon-over expressing cells 
close the gap slower than control cells over a monitoring period of 24 hours. 
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Figure 3.21 (A) Transwell migration assay of AZ521 cells showed that over-
expresses caldesmon decreased cell migration (***, p<0.001, n=3).  
(B) Matrigel invasion assay showed a decreased invasion in caldesmon-over 
expressing AZ521 cells (**, p<0.01, n=3). 
(C) Cell attachment assay showed caldesmon-over expressing cells adhere 







3.9 CO-IMMUNOPRECIPITATION IDENTIFIED CALDESMON-
INTERACTING PROTEINS 
 
Proteins that belong to the same biochemical pathways may interact and 
form functional clusters (Barabási et al., 2011). To identify the proteins that 
interact with caldesmon, we used caldesmon antibody to pull down the 
endogenous caldesmon expressed in FU97 cells. This cell line has high level of 
intrinsic caldesmon expression, and was thus chosen for the co-
immunoprecipitation study. A fraction of the cell lysates (input), unbound 
fractions, three eluates, three washes and the control eluate were resolved with 
SDS-PAGE and silver stained (Figure 3.22). The successful pull-down of 
caldesmon in the eluate was observed with Western blotting. Actin was identified 
in the eluate as well (Figure 3.23). 
In-gel digestion was carried out to identify the potential interacting partners 
of caldesmon. The silver-stained bands from the eluate were excised, subject to 
trypsin digestion and subsequent analysis by mass spectrometry. The protein IDs 
that correspond to their band locations were shown in Figure 3.24 and Table 3.4. 
The proteins include filamin B, an actin-binding protein that played a role in 
TGF-β signaling and angiogenesis (Del Valle-Pérez et al., 2010); myosins which 
were known to interact with caldesmon (Lin et al., 2009). Structural constituent 
proteins of podosome like α-actinin and tropomyosins (Tanaka et al., 1993) were 
also identified to be associated with caldesmon. Proteins that regulate the 
filamentous actin like villin1 (dos Remedios et al., 2003) and F-actin capping 
protein (Bretscher & Lynch, 1985) were identified to be potentially associated 
with caldesmon. Several heat shock proteins like HSPA5 (Wang et al., 2009), 
HSPA9 (Zong et al., 2012), HSPD1 were detected in the eluate. The findings 
reflect a cytoskeleton-regulating role of caldesmon together with other structural 
proteins. 
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Among the proteins identified by mass spectrometry, myosin 10 and 
tropomyosins are of interest to us. Myosin and tropomyosin are involved in 
regulating the actin cytoskeleton. Up-regulation of myosin 10 in MKN7 and 
AZ521 as compared to AGS and FU97 was observed by iTRAQ. To validate that 
these proteins interact with caldesmon, we performed western blotting to detect 
myosin 10 and tropomyosin in the lysates, eluate 1 and control eluate. As shown 
in Figure 3.25, myosin 10 (MYH10) and low molecular weight tropomyosin 
(LMW TPM) were detected in the eluate, which illustrates their interactions with 
caldesmon.  
We further probed for the expression level of myosin 10 and tropomyosin 
in AGS, FU97, MKN7 and AZ521 cell lysates with western blotting. As shown in 
Figure 3.26, in well/moderately differentiated gastric cancer metastasis versus 
primary cancer cell line (MKN7 versus AGS), myosin 10 expression was higher 
in metastasis derived MKN7 compared to its primary cancer derived counterpart 
AGS. Similarly, the expression of myosin 10 was higher in metastasis derived 
AZ521 compared to the primary cancer derived FU97 cells. The observed 
increased expression of myosin in metastatic gastric cancer cell lines is consistent 
with our findings obtained from iTRAQ. 
The tropomyosin antibody used here recognized both high molecular 
weight (HMW) and low molecular weight (LMW) tropomyosin. As shown in 
Figure 3.26, HMW tropomyosin was expressed in AGS, but not detected in its 
metastatic counterpart MKN7. Both HMW and LMW tropomyosin were 
expressed in FU97, only HMW tropomyosin was detected in its metastatic 
counterpart AZ521. Tropomyosin expression has often been down-regulated in 
transformed cancer cells (Bharadwaj & Prasad, 2002). The exact roles of each 








Figure 3.22 Silver staining of co-immunoprecipitation fractions: cell lysates 
input (1 µg), elutate 1, control eluate (with no antibody), eluate 2, eluate 3, 










Figure 3.23 Western blotting of co-immunoprecipitation fractions showed 
caldesmon was pulled down in the eluate 1 fraction. The input fraction’s 
presence of caldesmon was shown as the positive control. Actin was present in the 
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Figure 3.24 Protein identified by in-gel digestion coupled to mass 
spectrometry analysis. The proteins identified included filamin B, myosin 9, 
myosin 10, myosin 14, unconventional myosin-1c, alpha-actinin4, villin 1, 
caldesmon, HSPA5, HSPA9, HSPD1, actin, tropomyosin beta chain, 60S acidic 
ribosomal protein, tropomyosin alpha-1 chain, tropomyosin alpha-3 chain, 
tropomyosin alpha-4 chain, F-actin-capping protein subunit beta, peroxiredoxin-1 






Figure 3.25 Western blotting of co-immunoprecipitation fractions. Myosin 10 
and tropomyosin were pulled down in the eluate 1 fraction and they potentially 




Figure 3.26 Western blotting of myosin 10 and tropomyosin expression levels 
in the 4 gastric cancer cell lines. In well/moderately differentiated gastric cancer 
metastasis versus primary cancer cell line (MKN7 versus AGS), myosin 10 
expression was higher in MKN7 compared to AGS; whereas in poorly 
differentiated metastasis versus primary cancer cell (AZ521 versus FU97), the 
expression of myosin 10 was higher in AZ521 compared to FU97. Both high 
molecular weight (HMW) and low molecular weight (LMW) tropomyosin were 
detected here. HMW tropomyosin was expressed in AGS, but not detected in its 
metastatic counterpart MKN7. Both HMW and LMW tropomyosin were 
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UniProt Accession Protein MW(kDa) Unused Score %Cov Function 
sp|O75369|FLNB_HUMAN Filamin-B  278 47.97 11.7 Connects cell membrane constituents to the actin 
cytoskeleton. 
sp|P35579|MYH9_HUMAN Myosin-9  226 442.96 77 
Non-muscle cellular myosin. Play a role in cytokinesis, 
cell shape, secretion and capping 
sp|P35580|MYH10_HUMAN Myosin-10  229 165.55 61.6 
sp|Q7Z406|MYH14_HUMAN Myosin-14  228 104.08 49.1 
sp|O00159|MYO1C_HUMAN Unconventional 
myosin-Ic  
121 13.86 8.2 Actin-based motor molecules with ATPase activity, serve 
in intracellular movements 
sp|O43707|ACTN4_HUMAN Alpha-actinin-4  105 30.64 27 F-actin cross-linking protein, actin filament bundle 
assembly 
sp|P09327|VILI_HUMAN Villin-1  93 12 8.9 Epithelial cell-specific Ca2+-regulated actin-modifying 
protein, modulates the reorganization of microvillar actin 
filaments 
sp|P11021|GRP78_HUMAN 78 kDa glucose-
regulated protein 
HSPA5 
72 59.63 50.8 Facilitate the assembly of multimeric protein complexes 
inside the ER.  
sp|Q05682|CALD1_HUMAN Caldesmon  75 38.41 21.2 Regulation of actomyosin interactions. Stimulates actin 
binding of tropomyosin which increases the stabilization 
of actin filament structure 
sp|P38646|GRP75_HUMAN Stress-70 protein, 
mitochondrial 
HSPA9 
73 66.08 47.6 Implicated in the control of cell proliferation and cellular 
aging. May also act as a chaperone 




60 17.89 21.6 Implicated in mitochondrial protein import and 
macromolecular assembly. May facilitate the correct 
folding of imported proteins 
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sp|P63261|ACTG_HUMAN Actin, cytoplasmic 2  42 197.96 94.7 Actins are highly conserved proteins that are involved in 
various types of cell motility and are ubiquitously 
expressed in all eukaryotic cells. 
sp|P07951|TPM2_HUMAN Tropomyosin beta 
chain  
33 47.13 61.6 Binds to actin filaments in muscle and non-muscle cells. 
sp|P05388|RLA0_HUMAN 60S acidic ribosomal 
protein P0  
34 14.93 38.5 Ribosomal protein 
sp|P09493|TPM1_HUMAN Tropomyosin alpha-
1 chain  
33 53.97 65.1 
Binds to actin filaments in muscle and non-muscle cells. 
sp|P67936|TPM4_HUMAN Tropomyosin alpha-
4 chain  
28 42 66.9 
sp|P06753|TPM3_HUMAN Tropomyosin alpha-
3 chain  
33 24.68 49.3 
sp|P47756|CAPZB_HUMAN F-actin-capping 
protein subunit beta  
31 6.07 22.7  Bind in a Ca2+-independent manner to the fast growing 
ends of actin filaments (barbed end) thereby blocking the 
exchange of subunits at these ends 
sp|Q06830|PRDX1_HUMAN Peroxiredoxin-1  22 15.01 52.8 Involved in redox regulation of the cell. 
sp|P08590|MYL3_HUMAN Myosin light chain 3  22 14.73 61.5 Regulatory light chain of myosin. 
 
Table 3.4 Proteins identified from in-gel digestion of co-immunoprecipitation eluate.  MW represents the theoretical 
molecular weight extracted from UniProt. The unused score is a measurement of all the peptide evidence for a protein that is not better 
explained by a higher ranking protein. It is the true indicator of protein confidence; with a high unused score, protein is identified with 
more confidence. % Cov showed the percentage of matching amino acids from identified peptides having confidence greater than 0 




CHAPTER 4 DISCUSSION 
4.1 GASTRIC CANCER CELL LINES AS MODEL FOR PROTEOME 
PROFILING 
 
Proteins constituted the major players in the signaling pathways and 
various cellular processes, thus proteomics profiling is a valid approach in 
addressing many biological questions (Nishizuka et al., 2003). In our study, the 
proteins expressed by a panel of four gastric cancer cell lines were profiled. 
Cancer cell lines were utilized as disease model for proteomics profiling in many 
studies as cell lines are highly homogeneous compared to tissue samples, and can 
be easily cultured for protein harvesting.  
Our four gastric cancer cell lines consisted of two derived from primary 
cancer and two from lymph node metastasis with matched histopathologic 
subtypes. With 8-plex iTRAQ labeling technology, the four cell lines with their 
technical replicates were incorporated, allowing us to compare the protein 
expressions between metastasis and primary cancer in both poorly-differentiated 
and well/moderately-differentiated gastric cancer subtype. The technical 
replicates provided assurance for the robustness of iTRAQ labeling. Furthermore, 
the incorporation of four cell lines allowed us to cross-compare protein 
expressions among poorly- and well/moderately-differentiated gastric cancer cell 
lines. In previous cell line-based gastric cancer proteomics studies, only two cell 
lines were compared (Chen et al., 2006; Takikawa et al., 2006); the targets they 
identified may be confined to certain cell lines which may represent only one 
subtype of the disease.  
We have also verified the differentially expressed proteins caldesmon and 
fascin discovered by the proteomics method with other gastric cancer cell lines as 
well as in the clinical samples. The verification proved that our discovery based 
on cell lines can be extended with clinical relevance.  
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4.2 DIFFERENTIALLY EXPRESSED PROTEINS IN GASTRIC CANCER 
METASTASIS 
 
Comparing the cellular proteome of gastric cancer cell lines, we identified 
19 proteins were up- and 33 were down-regulated in both poorly- and 
well/moderately-differentiated metastatic gastric cancer cells. As shown in Table 
3.1, the differentially expressed proteins covered a wide spectrum of functions 
and were potentially associated with cancer progression as many of them were 
also found to be dysregulated in other types of cancer. The proteins that were 
over-expressed in metastatic gastric cancer cell lines belong to functional groups 
such as protein biosynthesis/transcription regulation (EEF1D, EIF5A2, EEF1G, 
EIF5A2), ribosomal proteins (RPL7A, RPL26, RPL32, RPL23A) protein 
chaperones (HSP90AB1), glycolytic enzymes (LDHA), calcium binding protein 
(ANXA1,ANXA5), protein involved in ubiquitin conjugation pathway (UCHL1), 
actin cytoskeleton proteins (FSCN1,MYH10). 
4.2.1 Up-Regulated Protein Functional Groups 
 
(1) Protein biosynthesis, transcription regulation. In our study, up-
regulation of eukaryotic elongation factor 1-delta (EEF1D) and eukaryotic 
initiation factor 5A2 (EIF5A2) in metastatic cell lines which are involved in 
protein synthesis were observed. In oesophageal carcinoma, higher expression of 
EEF1D mRNA is associated with lymph node metastases, advanced disease  
stages and poor prognosis (Ogawa et al., 2004). Over-expression of EIF5A2 is 
correlated with advanced stage of ovarian cancer (Guan et al., 2004).  
(2) Chaperone protein. Heat-shock protein 90 (Hsp90) has been involved in 
stabilization of multiple signaling proteins involved in oncogenesis (Kamal et al, 
2004). It has also been shown to be involved in regulating cell adhesion, cell 
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motility and angiogenesis and inhibition of Hsp90 led to anti-metastatic effect 
(Tsutsumi et al., 2009). 
(3) Glycolytic enzymes. Lactate dehydrogenase A (LDHA), which 
converted lactate from glucose metabolism to pyruvate, is up-regulated in 
metastatic gastric cancer cell lines in our study. In colorectal cancer, the level of 
serum lactate dehydrogenase and glycolysis are correlated with tumor 
angiogenesis and the expression of VEGFA and VEGFR (Azuma et al., 2007). 
Furthermore, knockdown of LDHA induced oxidative stress and inhibited tumor 
progression in human lymphoma (Le et al., 2010).  
(4) Proteins involved in calcium binding. Annexin A5 was up-regulated in 
metastatic gastric cancer cell lines found in our study. Expression of Annexin A5 
in colorectal cancer was associated with advanced cancer stage and poor 
prognosis (Xue et al., 2009). Knockdown of Annexin A5, a Ca
2+
 -binding protein 
in oral carcinoma cells led to decreased cell migration and invasion (Wehder et al., 
2009).  
(5) Proteins involved in ubiquitin-mediated protein degradation. The 
increased expression of UCHL1 was identified in renal cell carcinoma and non-
small lung cancer cells (Kim et al., 2009; Seliger et al., 2007). In non-small lung 
cancer cells, UCHL1 regulates tumor cell invasion by upstream activation of Akt 
(Kim et al., 2009).  
(6) Proteins regulating actin cytoskeleton. Fascin and myosin 10 were up-
regulated in metastasis-derived cancer cells. Fascin is involved in bundling of 
actin filament in cell migration and invasion, and it is over-expressed in advanced 
stage cancer (Darnel et al., 2009). Myosin 10 participates in maintaining cell 
shape and generates contraction forces for cell migration (Vicente-Manzanares et 
al., 2009). The up-regulation of these proteins may reflect increased cell motility 
during metastasis. 
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4.2.2Down-Regulated Protein Functional Groups 
 
The proteins which are down-regulated in metastasis-derived gastric cancer 
cells involve in a plethora of cellular functions: cell redox homeostasis (GSTP1), 
cytoskeleton (especially intermediate filament) proteins (EPPK1, KRT8, CALD1), 
extracellular matrix synthesis enzyme (SERPINH1), protein degradation/turnover 
(SERPINB1, LGMN, CTSA), ion transporters (CRIP1) etc. 
(1) Proteins involved in cell redox homeostasis. A down-regulation of 
glutathione S-transferase P (GSTP1) was observed in the metastasis derived 
gastric cancer cells. GSTP conjugated reduced glutathione to a the electrophilic 
centers of a spectrum of molecules, detoxifying their potential carcinogenic effect 
(Tew et al., 2011). A down-regulation of GSTP1 mRNA expression was observed 
in esophageal adenocarcinoma (Brabender et al., 2002). The expression level of 
GSTP1 were also lower in metastatic gastric carcinoma compared to the primary 
cancer found by tissue microarrays in 250 pairs of primary and metastatic gastric 
cancer tissues (Kim et al., 2009).  
(2) Cytoskeletal proteins. Epiplakin (EPPK1), keratin 8 (KRT8), caldesmon, 
are found to be down-regulated in metastasis-derived gastric cancer cells. EPPK1 
has been found to be a regulator of the intermediate filament (IF) network. 
Knockdown of epiplakin disrupted the IF networks in epithelial cells (Jang et al., 
2005). Keratin 8 is also a component of intermediate filament. Loss of keratin 8 
expression is associated with tumor metastasis and epithelial-mesenchymal 
transition (Fortier et al., 2013). Caldesmon interacts with cytoskeleton proteins 
actin, myosin, calmodulin and tropomyosin. Over-expression of caldesmon 
suppresses cancer cell invasiveness (Wang, 2008).  
(3) Protein involved in extracellular matrix synthesis. Serpin H1 
(SERPINH1) is involved in collagen synthesis progress, and a decreased 
expression of SERPINH1 was observed in metastasis derived gastric cancer cells.  
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(4) Proteins involved in protein degradation and turnover. Leukocyte 
elastase inhibitor (SERPINB1) is a serine protease inhibitor. The expression of 
SERPINB1 is down-regulated in gastric cancer tissues identified by microarray 
analysis (Wang et al., 2006). Cysteine protease legumain (LGMN) and serine 
protease cathepsin A (CTSA) are both found to be down-regulated in metastasis-
derived gastric cancer cells. These proteins are involved in lysosome-mediated 
protein degradation and participate in regulating apoptosis (Kirkegaard & Jäättelä, 
2009). 
(5) Ion transporters. Cysteine-rich protein 1(CRIP1) which is involved in 
intracellular zinc transport, has found to be down-regulated in metastasis-derived 
gastric cancer cells. Low CRIP1 expression in breast cancer is correlated with 
poor prognosis (Ludyga et al., 2013). Similarly, expression of CRIP1 in 
osteosarcoma patients indicates a better survival (Baumhoer et al., 2011). 
A wide range of protein expressions are perturbed when we compared 
metastasis-derived to primary cancer-derived gastric cancer cells, which indicates 
that metastasis progression affects global proteome expression and multiple 
cellular events and signaling pathways. From the functions of these dysregulated 
proteins, we may infer that an increased energy demand via glycolysis, a change 




4.3 FASCIN UP-REGULATION IN GASTRIC CANCER METASTASIS 
 
Of the differentially expressed proteins in metastasis-derived gastric cancer 
cells, fascin is worth noting because it is an actin cytoskeleton-associated protein 
and may play a role in regulating cell motility during the metastasis progression. 
With Western blotting (Figure 3.3, 3.4) and immunocytochemical (Figure 3.5) 
approaches, we observed that fascin was over-expressed in a panel of metastasis-
derived gastric cancer cell lines isolated from lymph nodes, liver metastasis and 
ascites. To extrapolate these findings from cell line models to clinical relevance, 
we analyzed the expressions of fascin with primary gastric cancer and their 
matching lymph node metastasis tissues (Figure 3.8, 3.9). The expression of 
fascin was found to be up-regulated when the tumor progressed from primary site 
to lymph node. Tumor invasion of lymph node is one of the critical events in 
gastric cancer metastasis, and it is the most important prognosis factor for patient 
survival (Coburn, 2009). We have discovered the expression level of fascin 
altered with regard to the lymph node metastasis of the tumors. Tissue microarray 
analysis confirmed that the expression of fascin is correlated with tumor serosal 
invasion and lymph node metastasis (Table 3.3), and in well/moderately 
differentiated gastric cancer patients, those with no expression of fascin have 
better survival compared to those with positive expression of fascin (Figure 3.10). 
These results obtained with clinical samples have established fascin as a protein 
of which the expression is correlated with gastric cancer metastasis, and it could 
possibly be served as a prognostic marker in gastric cancer patients 
Fascin is a 55 kDa actin-bundling protein. It is found to be up-regulated in 
ovarian, breast, thyroid and prostate cancers (Darnel et al., 2009). The elevated 
expression level of fascin is associated with advanced gastric cancer stage and 
poor prognosis (Hashimoto et al., 2004). Fascin is localized at the filopodia and 
regulates the number and morphology of filopodia (Vignjevic et al., 2006). It also 
plays a role in stabilizing the invadopodia, the invasive front for extracellular 
matrix degradation, and potentiated cell invasion. In fascin knockdown cells, 
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fewer invadopodia were formed with smaller size(Li et al., 2010). Knockdown of 
fascin with siRNA in gastric cancer cells decreased cell proliferation and cell 
migration (Fu et al., 2009). Recently migrastatin, an anti-cancer compound 
secreted by Streptomyces was found to inhibit fascin bundling of actin by 
competing with one of its actin-binding sites (Chen et al., 2010). Upstream 
signaling molecules including galectin-3 and TGF-β regulate fascin expressions. 
High expression of both galectin-3 and fascin were identified in gastric cancer 
tissues. Galectin-3 was found to be interacting with β-catenin/TCF and mediating 
the translocation of this complex into the nucleus, which subsequently promoted 
the expression of fascin (Kim et al., 2010). TGF-β-mediates fascin expression via 
JNK and ERK signaling and induces gastric cancer cell invasion and metastasis 
(Fu et al., 2009). Our proteomics and tissue immunohistochemistry results 
identified up-regulation of fascin which could be potentially associated with 
gastric cancer metastasis, and the findings agree with the above literature. 
However, since the current research on fascin in gastric cancer has been quite 




4.4 CALDESMON DOWN-REGULATION IN GASTRIC CANCER 
METASTASIS 
 
The proteomics study has identified caldesmon expression decreased in 
gastric cancer metastasis-derived cell lines (Figure 3.3). Caldesmon was found to 
be down-regulated in a panel of lymph node metastasis, liver metastasis, and 
ascites metastasis-derived gastric cancer cells compared to the primary cancer-
derived cells with Western blotting and immunocytochemistry (Figure 3.4, 3.5). 
An analysis of tumor tissues (matched primary cancer and lymph node metastasis) 
observed the decreased expression of caldesmon when the tumor developed 
lymph node metastasis (Figure 3.6, 3.7). In tissue microarray analysis, caldesmon 
expression was found in a small proportion of gastric tumor we examined, and 
most of the tumor cells didn’t express caldesmon. This could possibly mean that 
loss of caldesmon is an early stage event in gastric cancer.  
We have discovered the novel association of caldesmon expression with 
gastric cancer metastasis but the role of caldesmon in gastric cancer was unknown. 
Thus we performed functional studies of caldesmon using gastric cancer cell lines. 
Knockdown of caldesmon, which mimicked the advanced gastric cancer stage, 
has resulted in increased cell migration and invasion (Figure 3.13-3.15). Over-
expression of caldesmon, however, decreased the motility and invasiveness of 
gastric cancer cells (Figure 3.20, 3.21). These functional assays showed that the 
expression levels of caldesmon have an impact on the motility and invasiveness of 
gastric cancer cells, possibly exerting these effects by regulating the actin 
cytoskeleton. The effect of caldesmon in gastric cancer in vivo has not been 
studied yet. It is hypothesized that when the primary gastric cancer cells 
progressed into metastasis, the down-regulation of caldesmon will help the cancer 
cells gain more motility and cellular invasiveness which will facilitate metastasis 
progression. 
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Caldesmon is an actin-binding protein which localized to structures 
including stress fibers, membrane ruffles, podosome etc. Studies have found that 
caldesmon competes with Arp2/3 complex for actin binding and inhibites the 
formation of podosomes in RSV-transformed fibroblast cells (Hai & Gu, 2006).In 
transformed cells and cancer cells like human colon carcinoma (HCA7) and 
murine melanoma (B16F10) cell line, reduced caldesmon expression has been 
observed (Yoshio et al., 2007). In advanced stage breast cancer cell lines, 
caldesmon expression is reduced identified by a proteomics-based study (Geiger 
et al., 2012). Caldesmon down-regulation in the gastric tumor compared to 
adjacent normal tissue was identified with genomic profiling(Lee et al., 2003). 
Besides expression in tumor cells, caldesmon was found to be expressed in stroma 
vasculatures of various tumor types like glioma, stomach cancer, colon cancer etc., 
but not in normal blood vessels (Zheng et al., 2005). Caldesmon’s expression is 
observed in colon cancer stroma although its expression levels were not different 
between primary tumor and lymph node metastasis (Köhler, 2011). Knockdown 
of caldesmon in breast cancer and colon cancer cell line promoted cell invasion 
(Yoshio et al., 2007), while over-expression of caldesmon in cancer and fibroblast 
cells reduced podosome formation and subsequent decreased cell invasion (Lin et 
al., 2009). The factors that regulated caldesmon activity include various kinases 
and tumor suppressor gene p53. Cdk5 reduces caldesmon activity and 
subsequently promotes cancer cell invasion (Quintavalle et al., 2011). PFTK1, a 
CDC-2 related kinase, phosphorylates caldesmon, leading to its dissociation from 
actin and subsequent increase in hepatocellular carcinoma (HCC) cell migration 
(Leung et al., 2011). PKGIβ, a cGMP-dependent protein kinase, phosphorylates 
caldesmon and relieves its inhibition effect on myosin ATPase activity, resulting 
in increased breast cancer cell migration and invasion (Schwappacher et al., 2012). 
p53 up-regulates caldesmon expression, leading to the inhibition of podosome 
formation (Mukhopadhyay et al., 2009). Correlating the current literature with our 
findings, we proposed that caldesmon may be a potential metastasis repressor, and 
its role in gastric metastasis progression remains to be fully elucidated.  
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4.5 CALDESMON IN TUMOR STROMA OF GASTRIC CANCER 
PATIENTS 
 
In our immunohistochemical study, caldesmon expression is decreased in 
lymph node metastasis compared to its primary cancer counterparts (Figure 3.6, 
3.7). The expression of caldesmon has also been observed in the tumor stroma as 
well as net-like pericellular space. Tissue microarray analysis showed that the 
expression of caldesmon in pericellular space is positively correlated with tumor 
infiltration (Table 3.3). The role of caldesmon in tumor stroma remains to be 
determined. 
Tumor cells interact closely with their microenvironment - the tumor 
stroma which has a supportive role in carcinogenesis. The stroma includes 
inflammatory cells, cancer-associated fibroblasts (CAFs) which are responsible 
for the synthesis and modeling of the extracellular matrix (ECM) (Tlsty & 
Coussens, 2006) and cells that constitute the vasculature (Bhowmick & Moses, 
2005). During the carcinogenesis progression, the stromal is altered in response to 
the tumor, and an acquisition of α-smooth muscle actin, vimentin, smooth muscle 
myosin, calponin, tenascin and desmin expression has been found in tumor stroma. 
These proteins are often expressed as a response to wound healing or 
inflammation (Tlsty & Coussens, 2006). In pancreatic ductal adenocarcinoma 
(PDA), the host stromal response to an invasive tumor, including proliferation of 
the fibrotic tissue, and altered ECM conducive to the progression of tumor 
involves several key molecules including collagen type I, fibronectin, laminin, 
matrix metalloproteinases (MMPs), tissue inhibitors of MMP (TIMPs), TGF-β, 
platelet-derived growth factor (PDGF), chemokines, integrins etc.(Mahadevan & 
Von Hoff, 2007). These molecules could potentially be used in tumor diagnosis 
and targeted therapy. Of these molecules, MMPs’ increased expression was 
correlated with tumor invasion (Deryugina & Quigley, 2006). An 
immunohistochemical study using gastric cancer tissues revealed that the 
expression of MMP2and MMP9 were higher in malignant glands, and the 
99 
increased expressions are correlated with tumor recurrence and distant metastasis 
(Josson et al., 2010). Another study has identified in gastric cancer tissues, the 
tumor cells express PDGF-β, whereas the stromal cells (cancer-associated 
fibroblasts, pericytes, endothelial cells) express PDGF receptors (PDGFR-β). The 
administration of PDGFR tyrosine kinase inhibitor and cytotoxic drug decrease 
tumor growth and metastasis (Kitadai et al., 2011). The tumor stroma may also 
contribute to drug resistance. An impaired function of p53 in tumor stroma in a 
tumor xenograft model may be responsible for the tumor’s resistance to anti-
cancer drugs and contributed to stromal cell survival (Dudley et al., 2008).  
Caldesmon plays a part in the synthesis or modification of ECM (Ross et 
al., 2000). In colon cancer tissues, caldesmon expression was observed by 
immunohistochemistry in the stroma of primary tumor and metastases, and the 
expression was associated with proliferating cancer-associated fibroblasts (CAFs) 
(Köhler, 2011). The expression of caldesmon in pericellular space and stroma 
may have a different role compared to the role of caldesmon in tumor cells thus 
an expression variance was observed here. The role of caldesmon in tumor stroma 
may be studied with co-culturing of tumor cells with stromal cells which over-




4.6 CALDESMON MAY BE INVOLVED IN GASTRIC CANCER 
METASTASIS BY REGULATING THE ACTIN CYTOSKELETON AND 
INVADOPODIA 
 
With functional study coupled to cell assays, we have identified a 
decreased level of caldesmon expression promoted gastric cancer cell migration 
and invasion, and an increased expression of caldesmon inhibited the migration 
and invasion. Co-immunoprecipitation experiment discovered that caldesmon 
interacted with actin, myosin and tropomyosin which were involved in regulating 
the cytoskeleton, cell tension and invasion front such as invadopodia formation 
(Figure 3.9.3, 3.9.4, Table 3.4). 
A proposed model of caldesmon’s involvement in regulating the actin 
filaments is shown in Figure 4.1. Caldesmon, as an actin-binding protein, 
increases the cell rigidity via F-actin cross-linking (Greenberg et al., 2008). 
Caldesmon is found to be associated with invadopodia (an actin-enriched cellular 
protrusion which degrades the extracellular matrix), and negatively regulates 
invadopodia formation (Hai & Gu, 2006). The molecular mechanism of this 
regulation may be involving other actin-binding proteins including Arp2/3, 
myosin and tropomyosin. Caldesmon inhibits the binding of Arp2/3 complex 
which promotes actin polymerization and membrane protrusions (Yamakita et al., 
2003). Caldesmon also inhibites myosin (detected at invadopodia) binding to 
actin (Linder et al., 2011). The binding of myosin II to F-actin facilitates the cell 
contraction, which is critical for cell morphology reorganization and ECM 
remodeling (Olson & Sahai, 2009). Inhibition of myosin II activity with a 
chemical inhibitor blebbistatin results in abrogation of invadopodia-associated 
ECM degradation (Alexander et al., 2008). It is postulated that the actomyosin 
contraction may be involved in regulation of invadopodia and its associated 
mechanosensing (Linder et al., 2011). Caldesmon may inhibit invadopodia 
formation via interfering with myosin-mediated cell contraction. 
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Cellular protrusions like lamellipodia, filopodia and invadopodia are 
assembled by the actin filaments (Chhabra & Higgs, 2007). The invadopodia have 
a central core of F-actin with surrounding actin-binding proteins like Wiskott-
Aldrich syndrome protein (WASP) and WASP-interacting protein (WIP) (García 
et al., 2012), lipid raft-associated protein caveolin-1, membrane-binding matrix 
metalloproteinases MT1-MMP (Yamaguchi & Oikawa, 2010), vinculin, talin, α-
actinin, Src, gelsolin, Arp2/3 complex etc. (Buccione et al., 2004).Actin-binding 
proteins have important structural and functional roles in the cell such as 
maintaining cell shape and modulating cell movement. In carcinogenesis, the 
actin cytoskeleton has been altered (Wang & Coluccio, 2010) and the expressions 
of many actin-binding proteins are perturbed via signaling proteins such as Rac, 
Rho, and CDC42 which further induced changes in cell morphology and motility 
(Rao & Li, 2004). These proteins function as regulator of actin polymerization 
and assembly, or actin bundling/cross-linking (Rao & Li, 2004). Caldesmon may 
be one of these actin-binding proteins involved in regulating the cell dynamics. 
Invadopodia has been identified in numerous cancer cell lines derived from 
melanoma, breast cancer, glioma and head and neck squamous cell carcinoma 
(Stylli et al., 2008). In cancer cells, the ability of forming these invasive 
membrane protrusions is critical for the dissemination of cancer cells during the 
metastatic cascade (Klemke, 2012). These ventral cell protrusions adhere to and 
degrade the extracellular matrix with MMPs, thus facilitate cancer cell invasion 
(Yamaguchi & Oikawa, 2010). Unlike focal adhesions which cultured cells 
develop as organized sites of contact with substrate, invadopodia are more 
dynamic in formation and contain MMP for proteolytic degradation of ECM 
constituents (Buccione et al., 2004). Many factors regulate invadopodia formation. 
Growth factors such as PDGF, TGF-β and EGF induce invadopodia formation in 
cancer cells (Murphy & Courtneidge, 2011). Transcription factors like Twist 
induced PDGFRα expression which activates Src signaling and subsequent 
invadopodia formation (Eckert et al., 2011).It has been discovered that caldesmon 
may act downstream of p53 which suppresses invadopodia formation and 
extracellular matrix degradation (Mukhopadhyay et al., 2010).  
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Figure 4.1 A proposed model for caldesmon, myosin, tropomyosin and 
Arp2/3 in regulating the actin filaments, cell contraction and invadopodia 
formation. Caldesmon probably suppresses cancer cell migration and invasion by 
inhibiting with myosin-induced cell contraction and subsequent invadopodia 
formation. This figure was adapted from (Pawlak & Helfman, 2001) and created 
with tools from (www.proteinlounge.com). 
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4.7 CALDESMON INTERACTING PROTEINS IDENTIFIED BY CO-
IMMUNOPRECIPITATION 
 
The proteins that potentially interact with caldesmon have been identified 
by co-immunoprecipitation (Table 3.4). Many of these proteins are involved in 
regulating the actin cytoskeleton or cancer progression. We constructed an 
interaction network (Figure 4.2) based on the caldesmon-interacting proteins 
identified with STRING database (Szklarczyk et al., 2011). The network 
functions as actin cytoskeleton regulation. Tropomyosins, actin and myosins are 
directly linked to caldesmon in the network. Besides, the associations of the rest 
of the proteins with caldesmon are novel findings and the functional significance 
remains to be discovered. 
Many of the interacting proteins are involved in mediating cancer cell 
migration. Among these proteins, myosin and tropomyosin have been shown in 
the previous literature to be interacting directly with caldesmon (Wang, 2008). 
We performed Western blotting with the co-immunoprecipitation eluate, and 
verified caldesmon interacted with myosin10 and tropomyosin in gastric cancer 
cells. An over-expression of myosin10 was observed in the metastasis-derived 
gastric cancer cells. The loss of expression of low molecular weight tropomyosin 
in AZ521 and the loss of expression of both high and low molecular weight 
tropomyosin in MKN7 has been observed. The increased expression of myosin, 
the decreased expression of caldesmon and tropomyosin in cancer cells isolated 
from gastric cancer lymph node metastasis led us to postulate that caldesmon may 
co-operate with tropomyosin and oppose myosin’s pro-migratory activity in the 
metastasis progression. 
An increased myosin expression in gastric cancer metastasis-derived cell 
lines has been observed in our study. Non-muscle myosin II expresses in 
epithelial cells, encoded by MYH9, MYH10 and MYH14, has been involved in 
generating cytoskeleton tension (Clark et al., 2007), regulating cell polarity, cell 
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migration and cell-cell adhesion (Conti & Adelstein, 2008; Vicente-Manzanares 
et al., 2009). In fibroblast cells, myosin induces cell contraction which is inhibited 
by caldesmon (Helfman et al., 1999). Knockdown of myosin 9 and myosin 10 
with siRNA in breast cancer cells decreases cell migration (Betapudi et al., 2006). 
It has been proposed that the over-expression of myosin is correlated with gastric 
cancer cell migration. 
A plethora of tropomyosin isoforms are expressed in epithelial cells which 
are encoded by 4 genes tropomyosin α, β, γ and δ (Gunning et al., 2005). 
Tropomyosins protects actin filaments from been severed by gelsolin and cofilin 
(Wang & Coluccio, 2010). Tropomyosin is shown to be co-operatively binding to 
caldesmon, which promotes its association with the actin filaments (O’Neill et al., 
2008). In transformed cells, tropomyosin expression is down-regulated 
(Bharadwaj & Prasad, 2002). The down-regulation of tropomyosin in breast 
cancer may destabilize the structure of actin cytoskeleton and confer resistance to 
anoikis, which promotes the malignant growth of tumor (Raval et al., 2003). Our 
findings confirm tropomyosin’s interaction with caldesmon and they share the 
same down-regulation trend in metastasis-derived gastric cancer cell lines.  
Besides actin, myosin and tropomyosin which are shown to be interacting 
with caldesmon, novel targets including actin filaments regulating proteins and 
mechanosensor filamin B, invadopodia protein α-actinin, F-actin capping protein 
subunit beta (CAPZB), chaperone protein HSPA9 were identified to be 
potentially caldesmon-binding. These novel proteins identified here may play a 
role in gastric cancer metastasis via involving in the network that regulates the 
migration/invasion of gastric cancer cells together with caldesmon.  
Filamin B, which connects the plasma membrane with the actin filaments, 
is potentially involved in metastasis. Filamins are mechanosensors, and regulator 
of cell-cell adhesion and receptor-mediated signalling (Stevenson et al., 2012). In 
TGF-β induced epithelial-mesenchymal transition (EMT) in human lung cancer 
cells, the expression of filamin B, an actin polymerization regulator is up-
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regulated (Keshamouni et al., 2006). Knockdown of filamin B with siRNA in 
endothelial cells decreases cell migration ability (Del Valle-Pérez et al., 2010).  
α-actinin, an actin cross-linking protein, is localized to invadopodia 
(Schoumacher et al., 2010) and along stress fibers. In absence of α-actinin, the 
actin filaments are short and less organized (Vicente-Manzanares et al., 2009). α-
actinin is co-localized with tropomyosin and caldesmon (Bretscher & Lynch, 
1985). Knockdown of α-actinin-4 expression results in decreased cell migration, 
cell spreading and cell proliferation (Shao et al., 2010).  
F-actin capping protein subunit beta (CAPZB) is a regulator of filamentous 
actin growth. CAPZB stabilizes the length of actin filament by capping the barbed 
end (fast growing) of actin filament. The expression of CAPZB is down-regulated 
in 5-FU treated gastric cancer cells (Tseng et al., 2011).  
Stress-70 protein, mitochondrial, also known as HSPA9 or mortalin, is 
over-expressed in human lung squamous carcinoma with early recurrence (Zong 
et al., 2012) and advanced stage liver cancer. It may act as a protein chaperone, 
interacting with various key signaling proteins including p53, fibroblast growth 
factor-1 etc. (Yi et al., 2008).  
Identifying these interacting partners of caldesmon in gastric cancer 
metastasis reaffirmed the role of caldesmon as a potential regulator of cell 
migration and invasion by modulating the actin cytoskeleton dynamics with its 
interacting partners. The novel targets identified here may be studied further for 





Figure 4.2 Interaction network formed by caldesmon-interacting proteins 
identified. The network functions as actin cytoskeleton regulation. Stronger 




CHAPTER 5 CONCLUSION 
 
In this study, we used iTRAQ-based quantitative proteomics approach to 
profile the protein expression in a panel of 4 gastric cancer cell lines. Proteins that 
are differentially expressed among metastasis versus primary gastric cancer 
comprise of a spectra of cellular event: protein biosynthesis, transcription 
regulation, structural constituent of ribosome, RNA binding proteins, molecular 
chaperone, enzymes involved in glycolysis, TCA cycle, fatty acid metabolisms, 
actin cytoskeleton regulators, transporter proteins, calcium regulators etc. Among 
these proteins, fascin is over-expressed in metastasis-derived gastric cancer cell 
lines. The over-expression of fascin in gastric tumor tissues is correlated with 
advanced tumor stage and metastasis, and associated with poorer survival in 
patients with well/moderately differentiated gastric cancer.  
Caldesmon is down-regulated in metastasis-derived gastric cancer cell lines. 
Its expression in tumor cells decreases in lymph node metastasis tumor tissues 
compared to their primary tumor counterparts. The expression of caldesmon is 
also found in tumor stroma and its expression is associated with advanced tumor 
stage. 
Functional studies of caldesmon were performed in gastric cancer cell lines. 
Knockdown of caldesmon with siRNA in two primary cancer-derived cell lines 
increased the migration and invasion capacity of these cells. Over-expression of 
caldesmon in metastasis-derived cell line impaired cell migration and invasion, 
and increased the adhesion ability of cancer cells to the matrix.  
To discover proteins interacting with caldesmon, co-immunoprecipitation 
experiment was performed. We found that caldesmon interacted with actin, 
myosins, tropomyosins and other cytoskeleton-related proteins, protein 
chaperones to regulate the actin cytoskeleton. We propose that caldesmon could 
be potentially associated with gastric cancer metastasis by negatively regulating 
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the motility of cancer cells. Further functional analysis will be performed to 
elucidate the significance of the interactions. 
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CHAPTER 6 FUTURE STUDIES 
 
Despite the declining global incidence rates, gastric cancer still remains a 
health burden in Asia. Identification of metastasis-associated proteins is critical 
for understanding the molecular mechanisms underlying metastasis and early 
diagnosis of malignant progression. Our study has established caldesmon’s role as 
a potential player in gastric cancer metastasis. A functional cluster that interacted 
with caldesmon and regulated the actin cytoskeleton has been identified with co-
immunoprecipitation. Further studies to elucidate the role of caldesmon and to 
understand gastric cancer metastasis mechanism will be performed. Future work 
will involve (a) investigating caldesmon’s role in invadopodia formation with 
fluorescent gelatin degradation assay, (b) in vivo study of caldesmon’s role in 
tumor formation, (c) functional study of the caldesmon-interacting proteins 
myosins and tropomyosins with knockdown and over-expression. 
(a) Fluorescent gelatin degradation assay for invadopodia visualization 
Caldesmon may regulate the ECM-degrading cell protrusion called 
invadopodia. Proteolytic degradation occurred at these protrusions through matrix 
metalloproteinases, facilitating cancer cell invasion. The ECM degradation via 
invadopodia of cells that over-expressed caldesmon can be compared to control 
cells via plating cells on fluorescence-labeled gelatin matrix and visualizing the 
matrix degradation (non-fluorescence). The total degradation area may be 
quantified and compared. 
(b) In vivo study of caldesmon’s role in tumor formation 
The role of caldesmon in tumor formation may be studied in vivo. Cells 
that over-expressed caldesmon may be injected into nude mice, and the tumor size 
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comparing the tumor formation of caldesmon over-expression cells versus control, 
the role of caldesmon in vivo may be elucidated. 
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(c) Functional study of the caldesmon-interacting proteins myosins and 
tropomyosins 
Co-immunoprecipitation has identified myosin and tropomyosins as 
interacting partners of caldesmon in regulating the actin cytoskeleton. The 
functional role of myosin and tropomyosin may be studied with knockdown and 
over-expression experiments. Cell migration/invasion assays may be performed to 
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